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Abstract

Polypharmacy (PP), often defined as the use of five or more medications, is
highly prevalent in patients with cancer. As the quantity of medications for treating
cancer and comorbid conditions in patients with cancer become more numerous and
diverse, it is important to understand the various ways in which patient health and
economic outcomes may be adversely affected by prescribed medications. The
purpose of this dissertation was to investigate three distinct associations between PP
and the lives of patients living with cancer by estimating how PP (1) affects healthrelated quality of life (HRQoL), (2) is associated with healthcare expenditures, and (3)
affects health complications (HCs).

Approximately 25% of cancer survivors, individuals who were diagnosed with
cancer and are still alive, report a decreased quality of life related to physical
problems, and 10% report a decreased quality of life related to emotional issues,
compared to their noncancer counterparts (10% and 6%, respectively). Specifically,
cancer survivors report more mobility issues, inferior health, higher psychological
distress, and more mental health needs. There is scant published literature describing
PP in contributing to these outcomes. This study was conducted to address this gap to
better inform cancer survivors, care providers, and health policy decision makers.

Cancer was the sixth most expensive condition to treat in the United States
(US) in 2015. Most cancers are estimated to have a decreasing incidence and

increasing survival rate for the foreseeable future. A decreasing incidence may cause
overall cancer-related expenditures to decline over time, but the prevalence of cancer
coupled with the aging of the US population will result in an increase in the number of
cancer survivors. Thus, expenditures during treatment through end of life are expected
to continue to increase in coming years, as cancer survivors are estimated to increase
from 15.5 million in 2016, to 26.1 million by 2040.

Common cancer-related ailments such as pain, emesis, depression, venous
thrombosis, and seizures can require prescription medications. With additional
medications arises the risk for a health complication (HC). A HC, for the purposes of
this study, is defined as an adverse health problem related to a drug, including adverse
drug reactions, worsening of disease symptoms, falls, or overdoses. Although many
HCs are preventable, they represent approximately 125,000 hospitalizations, over 3.5
million physician office visits, and an estimated 1 million emergency department visits
each year in the general population. Previously identified risk factors for HCs in
people with cancer, depending on the type of cancer, include PP, advanced stage of
cancer, higher comorbidity, gender (for colorectal cancer), older age, and prior ER
visits or hospitalizations.

The purpose of the studies in this dissertation was to advance understanding of
the role of PP on health and economic outcomes among people with cancer. We
examined two data sources: (1) a large national survey database for manuscripts 1 and

2, and (2) a large, commercial claims database of privately-insured individuals for
manuscript 3; both of which included United States (US) populations.

Manuscript 1: The intent of this manuscript was to evaluate if an association
exists between PP and HRQoL in cancer survivors in the US. The analysis used selfreported answers to questions about various demographic and clinical information
captured in the Medical Expenditures Panel Survey (MEPS) database for even years
2008-2014. Respondents, who stated they were told that they had cancer, answered
questions from the SF-12v2 about their physical and mental health, which were
converted to the HRQoL measures PCS and MCS used for this analysis. This study
focused on comparing cancer survivors, defined as having ≥ 5 prescribed medication
classes in the year of the interview, with those with less than 5 medication classes.
Differences among types of cancer were also explored in both descriptive and
regression analyses. This study hypothesized that PP would lead to lower HRQoL as
compared to patients not having PP. Of 10.1 million survivors per year included in this
study, 45% were defined as having PP. We used ordinary least squares (OLS)
regression to estimate that PP was associated with a statistically and clinically
significant decrease in PCS scores among cancer survivors by 3.75 points. However,
PP was not associated with a significant decrease in MCS scores. As such, PP should
be analyzed closely in cancer survivors to ensure the best possible HRQoL.

Manuscript 2: Healthcare expenditures are increasing in the US, and that is
especially true for patients living with cancer. The objective of this manuscript was to

determine if PP was associated with increased direct health care expenditures, and if
differences in expenditure exist according to cancer type or setting of care. This aim
was accomplished by using the same years and source of data as Manuscript 1, while
modeling expenditure as a dependent variable. We hypothesized that PP was
associated with increased health expenditures in total, by type of cancer and by setting
of care. We used OLS regression with log transformed expenditures to obtain
estimates of association between PP and increased health expenditures controlling for
various demographic, socioeconomic, and clinical variables. PP was present in 43.9%
of the 10.6 million (per year) cancer survivors in the study. PP was associated with a
mean annual adjusted healthcare expenditure per cancer survivor of $13,266 (SD
$3,766), which was significantly higher than those without PP $8,573 (SD 5,082, pvalue <.0001). Cancer survivors with PP accounted for 70% of total healthcare
expenditures, yet only comprised 43.9% of the population.

Manuscript 3: This study focused on newly diagnosed patients with breast,
prostate, colorectal, or lung cancer and investigated if an association exists between
PP and nonfatal health complications (HCs). The data source used was Optum
Clinformatics® DataMart (Optum, Eden Prairie, MN, USA), years 2010-2015. The
database contains de-identified claims information with medical, prescription drug,
enrollment, and other data tables. PP was measured as the use of ≥ 5 prescribed
medication classes in the quarter (3 months) following incident cancer diagnosis. HCs
was the dependent variable in the analysis and included a range of medical conditions
known to be caused or worsened by effects of medications including falls, fractures,

gastrointestinal bleeding, and delirium. Descriptive and logistic regression analyses
were conducted to assess any associations between PP and HCs in a multivariable
framework. This study hypothesized that HCs would occur more frequently among
patients with PP than those without PP. In the primary analysis using multivariable
LR modeling, PP was associated with 31% increased odds (adjusted odds ratio: aOR)
of having ≥ 1 HCs, controlling for age, region, type of cancer, comorbidities, radiation
and chemotherapy treatments. PP was significantly associated with a higher risk of
having ≥ 1 HC in each cancer type (aOR: breast 1.37, 95% CI: 1.31-1.42; prostate
1.27, CI: 1.22-1.32; colorectal 1.26, CI: 1.16-1.36; lung 1.25, CI: 1.11-1.40). Active
chemotherapy was associated with significantly increased odds of ≥ 1 HC in colorectal
(aOR: 1.35, CI: 1.21-1.50) and lung (aOR: 1.33, CI: 1.15-1.54) cancers, but not
significantly associated with breast or prostate cancers. Newly diagnosed patients with
breast, prostate, colorectal, or lung cancer were all at a higher risk of having ≥ 1 HCs
if defined as having PP compared to those without PP. Active chemotherapy treatment
was associated with increased risk of HCs in colorectal and lung cancer patients, but
not in breast or prostate cancer patients.

Acknowledgements

I would like to thank my major professor and committee co-major member, Dr.
Stephen Kogut, for his help, guidance, and dedication in seeing me through the
dissertation process. I have gained substantial knowledge under his tutelage and will
be forever grateful. His knowledge of pharmaceutical medications was invaluable, as I
have no background in this area, and it was pivotal to this dissertation work. Dr. Kogut
is a world-class managed care pharmacist and researcher, and I simply could not have
chosen a better advisor as I navigated the world of pharmacoeconomics and health
outcomes research.
I would also like to thank my co-major committee member Dr. Ami Vyas for
her diligence in reviewing my work and providing helpful suggestions on topics I did
not know much about prior to this dissertation. She helped guide me through the
research process and always responded promptly whenever I had a question. Without
her assistance, I would not have been able to complete this research. For these things, I
will always be grateful.
In addition to my co-major committee members, I would also like to thank the
other members of my committee, Dr. Aisling Caffrey and Dr. Mary Greaney, for their
contributions in shaping this dissertation. Dr. Caffrey was also my mentor and leader
of my multi-year appointment as the database manager for our Health Outcomes group
within the College of Pharmacy. I learned a great deal in that time, especially how to
manipulate data and think more methodologically. Dr. Greaney helped shape my
dissertation with her years of experience as a researcher in health studies. Her

vii

suggestions helped me focus on the importance of both methods and the ability to
relay information to researchers in disciplines other than health outcomes.
I would be remiss if I did not mention my friends and previous graduates of the
program: Dr. Hilary Aroke, Dr. Ajinkya Pawar, and Dr.Yizhou Ye. Many times,
during this program and dissertation process, I felt overwhelmed by the sheer scope of
what lay before me. These individuals were always willing to speak, text, and email
with me to answer any questions. They have my sincerest gratitude.
Lastly, I would like to acknowledge both the support provided and sacrifices
made by my family and significant other during my time in the program at the
University of Rhode Island. I simply could not have accomplished this without them.

viii

Preface

The manuscript format was used to examine three distinct associations
between polypharmacy (PP), often defined as the use of multiple medications, and the
lives of patients living with cancer by estimating how PP (1) affects health-related
quality of life (HRQoL), (2) is associated with healthcare expenditures, and (3) affects
health complications (HCs). I hope this work is impactful.
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1.1 Abstract

PURPOSE: Polypharmacy (PP) is present in many cancer survivors and may lead to
lowered health-related quality of life (HRQoL). The objective of this study was to
evaluate the association between PP and HRQoL among non-institutionalized cancer
survivors living in the United States (US).
METHODS: A cross-sectional analysis of Medical Expenditure Panel Survey
(MEPS), a set of surveys of households, their medical providers and employers
throughout the US was conducted. Our analytic sample included all adult patients with
a clinical classification code for cancer, during even years 2008-2014. PP was defined
as reported use of five or more therapeutic classes of prescription medications. The
MEPS measured HRQoL using the Short Form 12-Item Health Survey Version 2 (SF12v2) Physical Component Summary (PCS) and Mental Component Summary (MCS)
scores. Ordinary least squares regression was used to assess associations between PP
and HRQoL controlling for various demographic, socioeconomic, and clinical factors.
RESULTS: An estimated 10.1 million cancer survivors per calendar year were
analyzed in this study. Cancer survivors were mostly white (81.8%), female (56.0%),
and under the age of 65 (51.6%). Female breast (17.2%), prostate (13.7%), and
melanoma (7.3%) were the most prevalent cancer types. PP was present among 44.4%
of cancer survivors. After adjusting for covariates, the mean PCS score for survivors
with PP was 35.8 points, which was significantly lower compared to those without PP
(39.5) by 3.7 points (p-value <.0001). Conversely, PP was not significantly associated
with differences in the mean MCS score compared to survivors without PP (44.9 vs.
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45.4, respectively) in multivariable regression analyses adjusting for demographic,
socioeconomic, and clinical variables.
CONCLUSIONS: Cancer survivors with PP accounted for approximately 45% of the
analyzed sample and had a significantly lower PCS score than their counterparts
without PP.
IMPLICATIONS FOR CANCER SURVIVORS: PP should be examined closely
by cancer survivors because of increased associations with poorer physical domain of
quality of life.
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1.2 Introduction

Approximately 25% of cancer survivors, individuals who were diagnosed with
cancer and are still alive, report a decreased quality of life related to physical problems
and 10% report a decreased quality of life related to emotional issues compared to
their noncancer counterparts (10% and 6%, respectively).1 Specifically, cancer
survivors report more mobility issues, inferior health, higher psychological distress,
and more mental health needs.1 They also worry about recurrence of their malignancy,
new types of neoplasms,2 and the possible long-term damage their cancer treatment
may cause.3 These concerns are additional to normal apprehensions about aging and
the occurrence of comorbidities.4 Approximately 70% of cancer survivors have one or
more comorbidities.5 Many observational studies have reported that cancer patients
have poorer survival if they have comorbidities.6

Cancer has a systemic impact on both body and mind.1 Treating these impacts
usually leads to greater use of prescription medications.7,8 Cancer patients may have
underlying comorbid conditions prior to their cancer diagnosis requiring medication
therapy. As the number of medications increases with medication therapy for cancer,
concurrent multiple medications treating both comorbid conditions and cancer may
lead to polypharmacy (PP). A cross-sectional study using the Medical Expenditure
Panel Survey (MEPS) database, estimated the prevalence of PP, defined by the study
as ≥ 5 unique prescription medications, to be 64% among cancer survivors, compared
to 51.5% in the non-cancer control group.5 The study found that the median number of
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unique prescription medications was 6 for cancer survivors, but only 4 for noncancer
controls, despite the majority (55%) of survivors having been diagnosed ≥ 5 years
previously.5

As cancer survivors receive an increased number of concomitant medications,
they become at an increased risk of dangerous adverse event occurrence.9 Concerns
about PP arise from certain harmful situations, such as when unforeseen or unintended
drug effects and drug-drug interactions result in health complications.10 Short-term,
long-term, and late effects of cancer treatments,11 related, in-part, to prescribed
chemotherapy regimens may also negatively impact cancer survivors.12 Treatment
effects include a wide variety of impacts to organs, tissues, body development,
growth, mood, feelings, actions, thinking, learning, memory, social and psychological
adjustment, and risk of second cancers.12 Treating these late effects to alleviate
discomfort can require additional medications such as analgesics for pain,13 and
corticosteroids to help breathe normally,14 among other drugs for symptoms which
may decrease health-related quality of life (HRQoL).1

A retrospective cohort study of adults (21 years and older) with arthritis
conducted using the MEPS, found that PP was associated with significantly lower
physical HRQoL scores.15 Based on this evidence and the negative impacts of cancer
on HRQoL, investigating the relationship between PP and HRQoL in the cancer
survivor population was warranted. The objective of this study was to evaluate this
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association between PP and HRQoL among cancer survivors living in the US using a
nationally representative survey database.
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1.3 Methods

Study design and data source
We used a multi-year cross-sectional study design to analyze the MEPS, a
publicly available database which contains survey questionnaire responses of deidentified non-institutionalized persons and their families (households), their medical
providers, and employers in the US.16 The MEPS includes five interviews over the
course of 2 calendar years conducted via computer assisted personal interviewing
(CAPI). The multiple interviews allow for (1) analyzing how people’s healthcare
changes over time and (2) minimizing recall bias.17 The MEPS also permits weighting
of the data to produce nationally representative estimates of the US population for
various healthcare analyses (e.g. expenditures, utilization of resources, insurance
plans).16

Two major components are included in the MEPS: household and insurance.16
We selected the longitudinal, medical conditions, and prescribed medicines files from
the household component for this study and linked them through a unique identifier
for each individual.16 We first used the medical conditions file to find individuals who
reported having been diagnosed with cancer by using the cancer specific clinical
classification codes; which are defined using the Clinical Classification Software
provided by the Agency for Healthcare Research and Quality (AHRQ) which clusters
diagnoses codes into a manageable number of categories.18 Respondents were defined
as cancer survivors during the interview process if they answered affirmatively to the
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question “Have you ever been told by a doctor or other health professional that you
had cancer or a malignancy of any kind?” Those who confirmed having, or had,
cancer were asked what type of cancer and their age at diagnosis.19 We also used
clinical classification codes and the International Classification of Diseases, 9th
Revision, Clinical Modification (ICD-9-CM) codes to identify concurrent chronic
conditions. Further details regarding MEPS have been described elsewhere.16

Sample selection
We combined the MEPS data for years 2008, 2010, 2012, and 2014 for our
analyses. In the MEPS process of interviewing, individuals are followed for two years,
therefore we selected even years to avoid including repeated observations.
Respondents with cancer other than nonmelanoma skin cancer, who were at least 18
years of age at the time of response, were included in this study. We excluded those
who had missing, negative, or zero person-level sample weights. To limit the effect of
multiple cancers on the estimated relationship between PP and HRQoL, individuals
were excluded if they had more than one type of cancer.19 We also excluded those
who died during the calendar year due to possible inflated prescription counts during
end-of-life care and the possible effect terminal cancer would have on HRQoL scores.
In one retrospective cross-sectional study of 4,252 hospice patients across 11 states in
the US, 35% of whom had cancer, the mean number of prescriptions was 15.20 Figure
1 shows a flowchart of inclusion and exclusion criteria.
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Measures
Dependent variable
Health-related quality of life
We chose the Physical Component Summary (PCS) and Mental Component
Summary (MCS) scores, calculated from the Medical Outcomes Study Short-Form 12
Health Survey Version 2 (SF-12v2) as our dependent variables. The SF-12v2 is
collected as part of the MEPS during rounds 2 and 4 of the survey to measure
HRQoL.21 Included in the survey for PCS are questions which focus on the general
health, mobility activity, limitations on activities or work, vitality, and pain. 21 The
MCS has questions regarding whether depression and anxiety have an impact on
accomplishments or work, mental health regarding feelings of calm and peacefulness,
and social activities limitations.21 PCS and MCS scores range from 0 to 100 and are
calibrated so that 50 is the mean score with a standard deviation of 10 for the general
US population.22 For both PCS and MCS scores, a higher score indicates a better
HRQoL. The SF-12v2 has been proven as both reliable and valid for measuring
HRQoL in the cancer survivor population using the MEPS.23

Key independent variable
Polypharmacy
A consensus definition of PP does not currently exist.24 Some investigators
have measured PP by individual drug or classes of medications.15,24
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The MEPS provides a prescriptions file with therapeutic medication class
information which are linked to the Multum Lexicon database for analysis.25 We used
these therapeutic class details to determine the maximum number of classes of
prescription medications the individuals were prescribed in one of the rounds that
coincided with our study years. We defined PP as using ≥ 5 therapeutic classes of
medications in one of the rounds of interviews, which is consistent with other
definitions in published literature.15,26

Covariates
Demographic variables included age group based on quartile analysis, sex,
race/ethnicity, geographic region, and marital status.

Socioeconomic variables included income, insurance status, and level of
education. A person’s income level was categorized as low, middle, or high; where
low indicates a person is below 200% above the poverty line, middle indicates 200%
to 400% above the poverty line, and high indicates 400% or greater income than the
poverty line. Insurance was categorized as privately-insured, uninsured, or publiclyinsured. Level of education was classified into 3 groups: less than high school (i.e. did
not graduate), high school graduate, and some college (must not have graduated to be
included).

Clinical variables included type of cancer, time since cancer diagnosis, select
chronic conditions common in cancer survivors, and number of total healthcare
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encounters. We classified cancer into several groups based on logical groupings or
sample size (if a specific type of cancer had too small a count to be its own subclass).
The cancer type groups were the following: breast, prostate and other male genitals
(included testicular cancer), cervical and other female genitals (included uterine,
ovarian, other female cancers), colon and other gastrointestinal (GI) (stomach, liver,
pancreas, and other GI cancers), melanoma, leukemias/lymphomas, and other or
unspecified (included lung) (Appendix A). We created a variable for time (years) since
cancer diagnosis by subtracting the person’s reported age at diagnosis from their
reported age at the time of the survey because it was found to be a significant indicator
of HRQoL among certain cancer groups.19 For patients who could not remember, or
otherwise did not provide a response for age at diagnosis, we used a statistical multiple
imputation procedure to assign time since cancer diagnosis.27 Multiple imputation is
an iterative process which uses the distribution of the observed data to estimate the
true value of the missing variable. Values produced were used in regression analysis
with the results pooled through statistical software to make valid inferences about the
parameters and standard errors. To fit the structure of the variable, we used a
minimum value of 0 (years) and maximum value of 85 (years). We achieved a relative
efficiency of 99.0% and 99.1% with 25 imputations for our PCS and MCS models,
respectively.28 Comorbidities were selected from a list of priority health physical
conditions provided by the MEPS and included the following: arthritis, chronic
obstructive pulmonary disease, diabetes, and heart disease/cardiovascular ailments.26
We chose these comorbidities based on MEPS’ recognition that they are more
prevalent, expensive, or especially relevant to healthcare policy as well as their impact
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on physical functioning.29 To assess the influence of mental health conditions in our
study population, we selected mood disorders (bipolar and depression) and anxiety
disorders, using the MEPS designated mental health disorders clinical classification
codes to identify these conditions for each patient (Appendix B). We dichotomized
these conditions as either present (1) or absent (0). Healthcare encounters were defined
as total provider or outpatient visits obtained from the household files and categorized
based on quartiles into the following groups: 0-4, 5-9, 10-19, and ≥ 20 visits.

Statistical analysis
We used chi-square tests to determine the statistical significance of differences
in presence or absence of PP for each independent variable (IV) according to statistical
significance (p-value <0.05). Analysis of variance (ANOVA) was used to assess the
relationship between the various levels of the categorical variables with the dependent
variables (DVs), where p-values <0.05 indicated a significant relationship. To estimate
the mean scores for PCS between those with or without PP, T tests were used
controlling for significant covariates. Mean PCS and MCS score differences by PP
with 95% confidence intervals were calculated as part of the T tests.

Univariate OLS regression models were used to test the significance of
association for each covariate by using the magnitude of the F value and p-value
statistic; whereby, significance of p-value < 0.10 resulted in the variable being
included in the multivariable OLS regression modeling process. If the variable was
significantly associated with both PP and PCS/MCS then they were held for further
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analysis in the modeling process. To ensure the IVs were not correlated with one
another the variance inflation factor (VIF), variance decomposition proportions
(VDFs), and condition indices (CNIs) options provided in the SAS procedural
software were used. If covariates had a VIF of ≥ 5.0, VDFs ≥ 0.5 (for two variables),
or CNI ≥ 30, collinearity would have been assumed and removal of one of the IVs
would have occurred.30 However, neither the PCS nor MCS models’ variables reached
these thresholds.

Multivariable OLS regression was used to evaluate the association between PP
and PCS/MCS scores controlling for all significant covariates. The ability to predict
physical or mental well-being by a covariate was judged by its p-value significance
level (p-value ≤ 0.05) in the multivariable modeling process. In the model building
process, covariates were included sequentially based on p-value and F-value
significance. If two covariates had the same p-value (e.g. <.0001), then the covariate
with the largest F-value was considered more significantly associated with the DV.
The adjusted model’s overall fit was measured using the coefficient of multiple
determination adjusted R2. When adding covariates to the model no longer produced a
better fitting model (higher adjusted R2 = better fit), a manual stepwise process was
implemented. This process involved removing a covariate which was significant in
univariate analysis, with a high F-value, but when added to the multivariable model
became insignificant. This stepwise technique was used until only significant
covariates were left. Parameter (beta, β) estimates with standard errors (SE) were used
to determine the direction and magnitude of association between PP and PCS/MCS
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scores. Parameter direction and magnitude were evaluated at each iteration of the
model building process to verify no multicollinearity existed, which would have been
evidenced by a large change in magnitude or direction, and/or a large jump in adjusted
R2 despite a variable not being significantly associated with the DV.

Due to the complexity of the survey design used in the MEPS; stratification,
clustering, and weighting were performed to control for clustering and unequal
probability design.31 Significance tests were all performed at the α = 0.05 level. All
analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC).
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1.4 Results

The study population consisted of an unweighted total of 3,281 adult cancer
survivors (Table 1). This sample represented approximately 10.1 million noninstitutionalized cancer survivors per calendar year living in the US. Weighted
percentages per annum for the 3 most prevalent specified types of cancer in the study
were breast (17.2%), prostate (13.7%), and melanoma (7.3%) with the largest single
group being other/unspecified (44.8%). Table 2 includes the proportions of all
independent variables in total by PP or no PP. The sex of the cancer survivors was the
only variable without significant difference between groups for those with or without
PP (p=0.4899). Older survivors (≥75) had PP in greater proportion (60.9%) than
younger survivors (18-49: 18.5%). Survivors of cervical cancer had the lowest
percentage of PP (38.1%); while survivors of leukemias and lymphomas had the
highest (50.1%). Approximately 60% or more of the survivors with PP also had
chronic conditions (arthritis 59.7%; COPD 69.7%; heart conditions 63.8%; diabetes
77.6%; anxiety 66.3%; mood 67.3%) which was significantly different than those
without PP (p-value <.0001). Of the cancer survivors included in this study, 1,460
(weighted N=4,471,359; 44.4%) reported use of ≥ 5 therapeutic classes of prescribed
medications. Table 3 highlights that the 10 most frequently reported therapeutic
classes of prescribed medications were very similar for those with PP and those
without. Between those with PP and those without PP, only 6 therapeutic classes
differed in total. In the PP group, the patients reported to be prescribed diuretics,
antidiabetic agents, and anticonvulsants more frequently compared to dermatological
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agents, antihypertensive combinations, and macrolide derivatives in the without PP
groups. The 10 most commonly prescribed therapeutic classes for those with PP made
up 42.8%, whereas those without PP was 48.3% of the total number of prescribed
therapies.

Adjusted mean PCS and MCS with mean differences by PP
Significantly lower mean PCS scores existed for all survivors with PP except
those with prostate cancer (Figure 2). Survivors of cervical and other female genital
cancers with PP had the lowest mean PCS score difference of 6.8 points [95% CI: 2.411.3], or 17.9%, compared to women without PP (31.1 [26.4-35.7] versus 37.9 [33.442.5], p-value 0.0027). Colon and other GI cancers had a similarly low mean PCS
score difference of 6.7 points [2.7-10.6], or 15.6%, in those with PP compared to those
without PP (35.8 [31.4-40.3] versus 42.5 [38.2-46.8], p-value 0.0012). Adjusted mean
MCS score differences by PP were not statistically significant for any individual type
of cancer. Adjusted mean PCS and MCS, as well as mean difference significance by
cancer type, with or without PP are depicted in Figure 2.

Associations between PP and PCS/MCS scores
Mean adjusted PCS scores for those with PP (35.76 [95% Confidence Interval:
34.30-37.23]) were significantly associated (p-value <.0001) with lower PCS scores
by 3.75 [2.63-4.87] points compared to those without PP (39.51 [37.97-41.06]) when
controlling for all variables associated with both PP and MCS/PCS in the model

16

(Table 4). No type of cancer was significantly different from their referent group of
leukemias and lymphomas for the PCS multivariable OLS model.

Table 4 provides the findings from the unadjusted and adjusted OLS regression
models to determine the significance of association between PP and PCS, controlling
for all investigated variables which had at least one group significantly different from
their referent group. Patients who were aged ≥ 75 had mean PCS scores which were
significantly lower than the youngest age group (18-34 years) by more than 3 points
(β= -3.35 SE 0.71 p-value <.0001) when controlling for all other significant variables
in the model. Survivors with arthritis (β= -4.76 SE 0.50 p-value <.0001), COPD (β= 4.36 SE 0.67 p-value <.0001), diabetes (β= -2.83 SE 0.62 p-value <.0001), and heart
conditions (β= -2.05 SE 0.53 p-value= 0.0001) had PCS scores significantly lower
compared to survivors without those comorbid conditions. Individuals with ≥ 20
healthcare encounters had PCS scores nearly 4 points lower than those with < 5
encounters (β= -3.71 SE 0.62 p-value <.0001).

In the multivariable regression model for MCS, mean MCS scores for those
with PP (44.90 [43.6-46.2]) were not significantly different than survivors without PP
(45.41 [44.1-46.8]), having a mean difference of 0.51 points lower ([0.49-1.51], pvalue= 0.3145), when controlling for all significant variables (Table 5). When
controlling for significant variables in the OLS model, colon or other type of GI
cancer was the only type of cancer significantly associated with MCS scores. The
scores for those with colon or other type of GI cancer were approximately 2.5 points
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lower than patients with leukemia or lymphoma (β= -2.34 SE 1.13 p-value= 0.0381).
This 2.5-point difference represents a clinically meaningful difference in physical
health from leukemia or lymphoma. Arthritis (β= -1.78 SE 0.41 p-value <.0001),
anxiety (β= -2.98 SE 0.67 p-value <.0001), and mood disorders (β= -8.08 SE 0.67 pvalue <.0001) were associated with significantly lower MCS scores in adjusted
analysis. Individuals with the lowest level of income had significantly lower MCS
scores compared to those with the highest income by over 3 points (β= -3.25 SE 0.53
p-value <.0001). Advanced age was associated with better MCS scores (50-64: β=
1.35 SE 0.58 p-value= 0.0196; 65-74: β= 3.93 SE 0.69 p-value= <.0001; and ≥ 75: β=
3.86 SE 0.71 p-value <.0001) compared to those 18-49 years old. Gender, race,
marital status, region, education, number of healthcare encounters, COPD, diabetes,
heart conditions, and time since cancer diagnosis were not significantly associated
with MCS.
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1.5 Discussion

Our study contributes to the literature by being the only research, to the
authors’ knowledge, examining the association between PP and HRQoL among adult
cancer survivors in the US using nationally representative survey data. The study
findings suggest that PP is associated with lower PCS scores by approximately 4
points among adult cancer survivors in the US. We were not surprised by these results
since management of chronic conditions among cancer survivors often requires
multiple prescription medications including nonsteroidal anti-inflammatory drugs,
benzodiazepines, antidepressants, and opioids, which often affect major organ
systems.5

Polypharmacy
We found that nearly half (44.4%) of cancer survivors were prescribed ≥ 5
distinct therapeutic classes of medications, thus were classified as having PP
according to our definition. We consider this to be a conservative estimate of the true
number of medications a patient was taking, as we did not count individual
medications, for which patients could be using multiple medications from the same
therapeutic class. In a systematic review of definitions for PP, 80.4% of 138 articles
had a numerical value for the definition, 10.9% had numerical along with duration of
therapy or healthcare setting, and 8.7% had descriptive definitions.24 The outcome of
the systematic review was that the most commonly used definition for PP was ≥ 5
daily prescription medications (46.4% of 110 articles meeting final inclusion

19

criteria).24 In a recently published survey study of 385 cancer survivors aged 70 or
older, where the researchers were evaluating ranges of PP cut-points to a range of
adverse events (falls, frailty) determined that using ≥ 5 medications concomitantly is
reasonable for identifying at-risk patients.32 Murphy et al. examined individual
medication counts among cancer survivors using the MEPS and found that
approximately 64% of cancer survivors were taking ≥ 5 distinct medications
concomitantly and had more physical limitation in adults 18 years and older.5
However, their study did not look at mental health conditions or PCS/MCS as
outcomes.

High pill burden has been associated with increased use of inappropriate
medication, thus increasing the risk of adverse outcomes.33 In a medical chart review
of 244 cancer patients aged ≥70 years receiving chemotherapy, 39% of severe
potential drug interactions involved chemotherapeutic agents.34 Additionally, the
authors found that cancer patients’ risk of a potential drug interaction increases with
each additional medication, up to 100% when 8 or more medications were being taken
concomitantly.34 These risk estimates are higher than those reported in noncancer
populations.34 However, not all PP can be considered inappropriate, as multiple
medication use does occur commonly in cancer survivors and may be the result of
appropriately treating multiple conditions. A closer look at the root causes should be
undertaken to try to eliminate excessive risks of inappropriate PP, such as lack of
integrated and coordinated care, and possible contraindicated drug-drug interactions,
which may lead to adverse events.35 Conversely, not addressing adverse situations
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requiring medications in a timely manner may lead to avoidable complications.
However, this study was not intended to address appropriateness of prescribed
medications and requires further investigation in the future.

PCS
Minimum clinically significant differences using the SF-12v2 range from 2-5
points from the population mean of 50.36,37 The difference in the adjusted analysis was
3.75 points, which met the lower bound of minimum clinically significant threshold.
This difference of 3.75 points represents the change in mean score of PCS with a oneunit change in PP (or a person switching from no PP to PP). Meaning that for someone
in the general population with a PCS score of 50 and without PP, reaching the PP
threshold of ≥ 5 unique classes of prescribed medications would be associated with
having a worse PCS score by 3.75 points and be a proxy for worse physical domain of
HRQoL.

We did not find any published study which evaluated the association between
PP and HRQoL in cancer survivors; however, a study had reported that cancer
survivors were more likely to have physical limitations (29.0% vs. 21.6%), and worse
overall health status than their noncancer counterparts (29.7% vs. 18.4%,
respectively).5 In this study, we found PP was associated with worse PCS scores, after
adjusting for comorbidity and age, among other covariates. As PCS is derived from
questions about both general health and physical specific, it is possible that PP
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decreases only specific areas covered by the PCS summary score. However, individual
items were not analyzed in this analysis.

MCS
PP was not significantly associated with changes in MCS scores in cancer
survivors compared to those without PP in our multivariable analyses, regarding
statistical or clinically meaningful differences. Colorectal cancer was the only type of
cancer which had a statistically and clinically meaningful difference in reported
mental and emotional health by more than 2 points compared to patients with
leukemia or lymphoma. According to LeMasters et al., who conducted a retrospective
cross-sectional analysis using the Behavioral Risk Factor Surveillance System
(BRFSS) survey, female colorectal cancer survivors have a significantly increased
number of days as perceived bad mental health in the past month compared to
matched noncancer controls.38 In a US population-based study, no difference was
found in quality of life scores between women with cervical cancer versus those
without.39 In our study, cervical cancer was not significantly associated with poorer
PCS or MCS scores compared to leukemias and lymphomas.

Previous research has shown significant associations among the covariates
included in this study, which was our basis for including them. For example, Weaver
et al., using the 2010 National Health Interview Survey, found that among 1,822 adult
cancer survivors who responded to the PROMIS Global 10, a 10-item patient-reported
outcomes survey, lower education and > 1 comorbidity were independently associated
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with poor physical HRQoL.1 Also, among their findings and consistent with ours is
that lower socioeconomic status was associated with poorer physical and mental
health. Weaver et al. also found that younger age was associated with poorer mental
health. Lastly, the Weaver et al. study found no differences among races/ethnicities for
either physical or mental health and measurements of quality of life, a finding similar
to what we found in multivariable analysis.1 In a study by Wang et al. conducted using
the MEPS data, of 3,610 cancer survivors, the prevalence of each cancer type was
similar to this study where 20.1% had breast, 15.0% had prostate, and 8.4% had
melanoma.19

PP in cancer survivors has been a concern for many years and this study
confirms that use of multiple medications is still highly prevalent and warrants further
attention in all cancer survivors. More consideration should be paid to continuity of
care for cancer survivors to ensure appropriate medication use and non-medication
management for chronic conditions. The study findings support the need for future
research aimed at identifying the classes of prescription medications and the clinically
significant drug-drug interactions that may cause survivors to report decreased
physical QoL measured by PCS scores. Therefore, healthcare providers should
evaluate the benefits and harms of prescribing multiple medications for cancer
survivors.
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1.6 Limitations

Some limitations exist due to the nature of the data source. As the MEPS has a
survey design depending on a person’s ability to remember various life events,
responses are subject to recall bias. Also, the MEPS does not capture information on
stage or severity of cancer which affects both PP and HRQoL, and so we could not
adjust for these variables in our analyses. PP was not assessed for association with
responses to specific mental or physical health states from the SF12-v2 since we used
the summarized scoring totals for PCS and MCS; therefore, we cannot allude to any
specific physical or mental functioning that may have been impacted by PP. Despite
controlling for various comorbidities, severity of those illnesses could not be captured.
We cannot make assumptions as to a causal effect that the cancer treatment, or the
cancer itself, may have had on specific chronic conditions.

As we evaluated the association between PP and HRQoL among cancer
survivors by therapeutic class, some information may have been lost due to multiple
drugs being used within the same class. Also, because this was cross-sectional, we
cannot determine if an individual’s PCS or MCS scores changed over time with the
addition or subtraction of medications. As PP is a proxy for measure of disease
burden, it is likely that survivors were appropriately taking multiple medications to
help address comorbid conditions rather than their comorbid conditions were due to
taking so many medications. However, this paper’s intent was not to address
appropriate versus inappropriate PP, hence further research is needed to better

24

understand PP’s impact on HRQoL. Though the association between cancer and PP
has been reported previously,5 to our knowledge, no study had evaluated how PP is
associated with HRQoL among adult cancer survivors in the US.
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1.7 Conclusion

In this cross-sectional study of community-dwelling cancer survivors in the
US, PP was associated with lower PCS scores in certain types of cancer and those with
higher comorbidity burden. Cancer survivors, their support system, providers, and all
other pertinent stakeholders should have a vested interest in understanding how PP
impacts the survivors’ lives to maximize HRQoL. PP should be examined closely by
cancer survivors because of possible increased associations with poorer physical
domain of quality of life.
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Figure 1. Selection of Patients for Analyses of Prevalence of Polypharmacy in Adult Cancer
Survivors (≥ 18 years) (2008, 2010, 2012, 2014), unweighted.
5,664 Adults who had been
diagnosed with cancer in their past;
identified from interview years 2008,
2010, 2012, 2014
113 (2.0%) Excluded patients with
zero person-weight information.
5,551 (98.0%) All cancer survivors
with a valid person weight

1,844 (33.2%) Excluded patients
with nonmelanoma skin cancer
(1,183; 21.3%) or more than one type
of cancer diagnosis (659; 11.9%);
men with breast cancer (2; <0.1%).

3,707 (65.5%) All valid cancer
patients of interest
426 (11.5%) Excluded patients who
had an invalid PCS or MCS score
(190; 5.1%), missing age (112;
3.0%), < 18 years (70; 1.9%), died in
round (53; 1.4%), or age at diagnosis
was > current age (1; <0.1%).

3,281 (57.9%) Adult Cancer
Survivors in Study Sample

1,821 (55.5%)
No Polypharmacy

1,460 (44.5%)
Polypharmacy
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Table 1. Distribution of Cancer Diagnoses in Adult Cancer Survivors (≥ 18 years) (2008, 2010,
2012, 2014) of Interest Available in MEPS.
Type of Cancer
N (%), weighted
Breast
1,730,969 (17.2%)
Prostate and other male genital
1,382,904 (13.7%)
Cervical and other female genital
594,733 (5.9%)
Colon and other GI
644,921 (6.4%)
Melanoma
731,028 (7.3%)
Leukemias and lymphomas
467,401 (4.6%)
Other / unspecified
4,524,103 (44.9%)
Total
10,076,059 (100.0%)
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Table 2. Demographic and Clinical Characteristics of Adult (≥ 18 years) Cancer Survivors (N=
10,076,059) with Cancer Diagnoses of Interest 2008, 2010, 2012, 2014, Weighted n (%).
Demographic and Clinical
Characteristics
No Polypharmacy
Polypharmacy
p-valuee
Total
n= 5,604,700 (55.6%)
Age group (years)a
18-49
1,667,385 (81.5)
50-64
1,881,319 (59.6)
65-74
1,161,289 (44.9)
≥ 75
894,707 (39.1)
Sex
Men
2,430,618 (54.8)
Women
3,174,081 (56.2)
Race
White
4,552,749 (55.3)
African American
399,601 (50.4)
Hispanic
402,539 (63.5)
Other
249,810 (60.8)
Region
Northeast
1,192,725 (57.9)
Midwest
1,161,836 (52.6)
South
1,876,790 (52.1)
West
1,373,348 (62.2)
Type of Cancerb
Breast
905,173 (52.3)
Prostate/other male genital
700,133 (50.6)
Cervical/other female genital
367,847 (61.9)
Colon/other gastrointestinal
331,340 (51.4)
Melanoma
445,029 (60.9)
Leukemias and Lymphomas
233,040 (49.9)
Other/unspecified
2,622,137 (58.0)
Healthcare Encounters
≤4
1,763,347 (81.9)
5-9
1,671,371 (64.3)
10 - 19
1,352,039 (47.8)
≥ 20
817,943 (32.8)
Marital Status
Married
3,554,793 (57.9)
Not Married
2,049,907 (52.1)
Education Level
Less than High School
2,524,157 (52.7)
High School
909,690 (50.2)
Some College
2,170,853 (62.4)
Income Levelc
Low
1,327,712 (46.5)
Medium
1,472,878 (55.1)
High
2,804,110 (61.7)
Insurance Coverage
Private
4,175,600 (59.5)
Uninsured
316,594 (84.9)
Public
1,112,506 (41.4)
Time since cancer diagnosis (years)
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n= 4,471,359 (44.4%)
<.0001
377,514 (18.5)
1,277,488 (40.4)
1,425,711 (55.1)
1,390,646 (60.9)
0.4899
2,002,535 (45.2)
2,468,825 (43.8)
0.0143
3,685,943 (44.7)
393,249 (49.6)
231,205 (36.5)
160,962 (39.2)
0.007
866,216 (42.1)
1,047,874 (47.4)
1,723,153 (47.9)
834,117 (37.8)
0.0415
825,795 (47.7)
682,770 (49.4)
226,886 (38.1)
313,581 (48.6)
285,999 (39.1)
234,362 (50.1)
1,901,966 (42.0)
<.0001
389,527 (18.1)
927,650 (35.7)
1,475,045 (52.2)
1,679,137 (67.2)
0.0062
2,584,969 (42.1)
1,886,390 (47.9)
<.0001
2,261,309 (47.3)
901,685 (49.8)
1,308,365 (37.6)
<.0001
1,525,131 (53.5)
1,201,854 (44.9)
1,744,374 (38.3)
<.0001
2,840,116 (40.5)
56,407 (15.1)
1,574,836 (58.6)
0.0005

≤2
3-5
6 - 10
> 10
Arthritisd
Yes

1,013,155 (58.2)
1,023,246 (57.1)
1,826,313 (58.3)
1,741,987 (51.0)

727,923 (41.8)
767,357 (42.9)
1,305,332 (41.7)
1,670,750 (49.0)

1,806,317 (40.3)

2,670,963 (59.7)

<.0001

COPDd
<.0001
Yes
537,824 (30.3)
1,235,408 (69.7)
Diabetesd
<.0001
Yes
442,667 (22.4)
1,531,746 (77.6)
Heart conditionsd
<.0001
Yes
2,112,035 (36.2)
3,717,153 (63.8)
Anxiety disordersd
<.0001
Yes
517,393 (33.7)
1,019,466 (66.3)
Mood (depression + bipolar)d
<.0001
Yes
555,323 (32.7)
1,140,712 (67.3)
Notes: aThe Medical Expenditures Panel Survey sets an upper limit of 85 years old.
b
Type of cancer included the following categorizations: prostate (included testicular cancer and
cancer of other male genitals), cervical (included uterine, ovarian, other female cancers), colorectal
(esophageal, stomach, colon, rectum and anus, liver and intrahepatic bile duct, pancreas, and other
gastrointestinal cancers).
c
Income level: low (<200% above poverty line), medium (200% to 400% above poverty line), high
(>400% above the poverty line).
d
Arthritis, chronic obstructive pulmonary disease (COPD), diabetes, heart conditions, anxiety and
mood disorders are binary values (No=not present, Yes=present) listed in Appendix B.
e
Chi-square statistics were used to assess significant differences.
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Table 3. The 10 Most Frequently Prescribed Therapeutic Classes by Polypharmacy in US Adult
(≥ 18 years) Cancer Survivors for 2008, 2010, 2012, 2014 (N=10,076,059), weighted n %.
No Polypharmacy
Polypharmacy
Therapeutic Class
n
%
Therapeutic Class
n
%
Analgesics
5,641,955
9.8
Antihyperlipidemic
10,756,303
7.0
Agents
Antihyperlipidemic
5,271,895
9.1
Analgesics
10,026,041
6.5
Agents
Thyroid Hormones
2,594,923
4.5
Beta-Adrenergic
6,880,568
4.5
Blocking Agents
Antidepressants
2,568,521
4.4
ACEIs
6,191,953
4.0
Beta-Adrenergic
2,162,874
3.7
Antidepressants
6,059,182
3.9
Blocking Agents
ACEIs
2,011,395
3.5
Proton Pump Inhibitors
6,008,914
3.9
Dermatologic Agents
2,002,805
3.5
Diuretics
5,734,144
3.7
Proton Pump Inhibitors
1,961,436
3.4
Antidiabetic Agents
5,501,999
3.6
Macrolide Derivatives
1,875,861
3.2
Anticonvulsants
4,701,619
3.0
Antihypertensive
1,811,742
3.1
Thyroid Hormones
4,348,843
2.8
Combinations
Notes: ACEIs = Angiotensin Converting Enzyme Inhibitors.
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Physical Component Score

Mental Component Score

Figure 2. Adjusted Mental and Physical Component Scores by Cancer Type, with or without
Polypharmacy, Means with 95% Confidence Interval Bars (N =10,076,059).
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* = statistically significant mean differences between mean scores at alpha = 0.05. NoPP = No
polypharmacy. PP = polypharmacy.
Type of cancer included the following categorizations: prostate (included testicular cancer and cancer
of other male genitals), cervical (included uterine, ovarian, other female cancers), colorectal
(esophageal, stomach, colon, rectum and anus, liver and intrahepatic bile duct, pancreas, and other
gastrointestinal cancers).
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Table 4. Unadjusted and Adjusted Regression Estimates (Beta) with Standard Errors (SE) of
Significant Explanatory Variables Based on an Ordinary Least Squares Regression Model for
Patient and Clinical Factors Associated with Physical Component Scores (PCS) in US Adult
Cancer Survivors (≥ 18 years) for 2008, 2010, 2012, 2014 (N=10,076,059).
Explanatory Variables
Polypharmacy
Yes
Age Group, years
18-49
50-64
65-74
≥ 75
Region
Northeast
Midwest
South
West
Education Level
Less than High School
High School
Some College
Income Levela
Low
Medium
High
Insurance Coverage
Private
Public
Uninsured
Arthritisb
Yes

Unadjusted Model
Beta (SE)
P value

Adjusted Model
Beta (SE)
P value

-10.23 (0.51)

<.0001

-3.75 (0.57)

<.0001

Reference
-3.83 (0.69)
-6.19 (0.72)
-9.99 (0.69)

<.0001
<.0001
<.0001

-1.29 (0.58)
-0.92 (0.65)
-3.35 (0.71)

0.0277
0.1600
<.0001

Reference
-2.22 (0.83)
-2.69 (0.71)
0.23 (0.77)

0.0085
0.0002
0.7610

-1.28 (0.76)
-1.84 (0.65)
0.24 (0.67)

0.0951
0.0050
0.7216

-4.28 (0.53)
-5.84 (0.78)
Reference

<.0001
<.0001

-1.16 (0.44)
-2.98 (0.64)

0.0097
<.0001

-7.80 (0.64)
-3.51 (0.61)
Reference

<.0001
<.0001

-3.65 (0.63)
-1.58 (0.53)

<.0001
0.0034

Reference
-7.16 (0.60)
-0.82 (1.30)

<.0001
0.5289

-2.56 (0.56)
-2.27 (1.16)

<.0001
0.0518

-8.72 (0.47)

<.0001

-4.76 (0.50)

<.0001

COPDb
Yes
-8.62 (0.73)
<.0001
-4.36 (0.67)
<.0001
Heart Conditionsb
-8.01 (0.52)
Yes
<.0001
-2.83 (0.62)
<.0001
Diabetesb
-7.50 (0.66)
Yes
<.0001
-2.05 (0.53)
<.0001
Healthcare Encounters (no. of visits)
Reference
0-4
-1.32 (0.63)
0.0381
5-9
0.57 (0.51)
0.2716
-5.17 (0.71)
<.0001
10 - 19
-0.69 (0.57)
0.2299
-8.80 (0.76)
<.0001
≥ 20
-3.71 (0.62)
<.0001
Notes: aIncome level: low (<200% above poverty line), medium (200% to 400% above poverty line),
high (>400% above the poverty line).
b
Chronic physical condition is a binary value (No=not present, Yes=present) for the conditions listed
in Appendix B.
The model fit was measured by its adjusted R2 value (0.35).
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Table 5. Unadjusted and Adjusted Regression Estimates (Beta) with Standard Errors (SE) of
Significant Explanatory Variables Based on an Ordinary Least Squares Regression Model for
Patient and Clinical Factors Associated with Mental Component Scores (MCS) in US Adult
Cancer Survivors (≥ 18 years) for 2008, 2010, 2012, 2014 (N=10,076,059).
Explanatory Variables

Unadjusted Model
Beta (SE)
P value

Adjusted Model
Beta (SE)
P value

Polypharmacy
-2.84 (0.43)
<.0001
-0.51 (0.51)
0.3145
Yes
Age Group (years)
Reference
18-49
1.21 (0.61)
0.0467
50-64
1.35 (0.58)
0.0196
3.40
(0.66)
<.0001
65-74
3.93 (0.69)
<.0001
3.05 (0.59)
<.0001
≥ 75
3.86 (0.71)
<.0001
Time Since Cancer Diagnosis (years)
-1.78 (0.58)
0.0025
-1.64 (0.66)
0.0133
0-2
Reference
3-5
-0.36 (0.46)
0.4358
-0.34 (0.61)
0.5691
6-10
-1.21 (0.51)
0.0178
-1.01 (0.71)
0.1514
≥ 11
Income Levela
-5.49 (0.52)
<.0001
Low
-3.25 (0.53)
<.0001
-2.50 (0.54)
<.0001
Medium
-1.47 (0.49)
0.0029
Reference
High
Insurance Coverage
Reference
Private
-2.90 (0.49)
<.0001
Public
-1.27 (0.50)
0.0108
-4.57
(1.20)
0.0002
Uninsured
-1.29 (1.12)
0.2473
Type of Cancerb
1.08 (1.20)
0.3696
Breast
1.10 (1.15)
0.3354
-1.50
(1.31)
0.2546
Cervical/other female genital
0.85 (1.24)
0.4907
-2.66 (1.29)
0.0413
Colon/other gastrointestinal
-2.34 (1.13)
0.0381
1.84
(1.43)
0.2009
Melanoma
0.53 (1.21)
0.6619
0.08 (1.09)
0.9401
Other/unspecified
0.28 (1.02)
0.7843
2.42 (1.18)
0.0405
Prostate/other male genital
0.74 (1.15)
0.5224
Reference
Leukemias and Lymphomas
Arthritisc
-3.11 (0.46)
<.0001
Yes
-1.78 (0.41)
<.0001
d
Anxiety Disorders
Yes
-5.88 (0.73)
<.0001
-2.98 (0.67)
<.0001
Mood Disordersd
-10.1 (0.68)
<.0001
<.0001
Yes
-8.08 (0.67)
a
Notes: Income level: low (<200% above poverty line), medium (200% to 400% above poverty line),
high (>400% above the poverty line).
b
Type of cancer included the following categorizations: prostate (included testicular cancer and
cancer of other male genitals), cervical (included uterine, ovarian, other female cancers), colorectal
(esophageal, stomach, colon, rectum and anus, liver and intrahepatic bile duct, pancreas, and other
gastrointestinal cancers).
c
Arthritis is a binary value (Yes=present) and is listed in Appendix B.
d
Anxiety and mood disorders are listed in Appendix B.
The model fit was measured by its adjusted R2 value (0.22).
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2.1 Abstract

PURPOSE: Prescription medications play a vital role in the lives of cancer survivors.
However, they also contribute to rising healthcare expenditures in the United States
(US). The objective of this study was to determine if polypharmacy (PP) is associated
with increased healthcare expenditures among cancer survivors in the US.
METHODS: A cross-sectional study analysis of data from the Medical Expenditure
Panel Survey (MEPS), a set of surveys of non-institutionalized individuals,
households, their medical providers and employers throughout the US was conducted.
The analytic sample included all patients 18+ years of age who had a diagnosis code
for a single type of cancer, excluding nonmelanoma skin cancers, during even years
2008-2014. PP was defined as the reported use of ≥ 5 distinct therapeutic classes of
prescribed medication during the panel (year). Healthcare expenditures were measured
as the total direct payments per annum from all reported sources in 2017 dollars. We
used ordinary least squares regression with log transformed expenditures as our
dependent variable adjusting for various demographic and clinical variables.
RESULTS: PP was present in 43.9% (10.6 million, weighted per year) of cancer
survivors included in this study. The per annum total direct medical expenditures for
all cancer survivors in the US was $162.6 billion. The mean annual adjusted
healthcare expenditures per cancer survivor with PP was $13,266 (SD $3,766), which
was significantly higher than those without PP $8,753 (SD $5,082, p-value <.0001).
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CONCLUSION: Cancer survivors with polypharmacy accounted for 70% of total
annual medical expenditures among cancer survivors. PP was associated with higher
expenditures across cancer types, intensity of utilization, and setting of care.
IMPLICATIONS FOR CANCER SURVIVORS: Cancer survivors should be aware
that increased prescription medication use is associated with increased total healthcare
expenditures.
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2.2 Introduction

National health expenditures in the United States (US) increased by 3.9% from
2016 to 2017, and made up 17.9% of gross domestic product, totaling $3.5 trillion
dollars according to the Centers for Medicare and Medicaid Services (CMS).1 On
average, this amounted to $10,739 per person in the US.1 The estimated 2017 national
expenditures on cancer care was $147.3 billion and is expected to increase to $157.8
billion in the Medicare population alone by 2020.2

Cancer was the sixth most expensive condition to treat in the US in 2015.3
Most cancers are estimated to have a decreasing incidence and increasing survival rate
for the foreseeable future.2 A decreasing incidence may cause overall cancer-related
expenditures to decline in the long run, but the prevalence of cancer coupled with the
aging of the US population will result in an increase in the number of cancer
survivors. Thus, increases in expenditures during treatment through end of life, the
period of time which defines a cancer survivor,4 are expected to continue to increase in
coming years,2 given that cancer survivors are estimated to increase from 15.5 million
in 2016,4 to 26.1 million by 2040.5

Cancer survivors face several major challenges including financial hardship,
body image/self-esteem issues, and anxiety surrounding fears of long-term side-effects
of treatment and cancer recurrence.6 As part of some cancer survivors’ treatment plans
(e.g. breast cancer), they may take medications (adjuvant hormonal therapy) for the
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following 5 to 10 years to lower the risk of recurrence.7 Adjuvant therapy, for
example, may increase the quantity of medications the survivor is to define them as
having polypharmacy (PP), most commonly defined as the use of ≥ 5 concomitant
medications.8 Because survivors may have already been taking numerous medications
to treat comorbid conditions and for palliative care one additional medication may
now qualify as reaching the PP threshold.9 PP is known to be highly prevalent and is
associated with higher prescription costs among cancer survivors.10

The types of services and healthcare products cancer survivors require
included in the national health expenditure estimates are hospital care, physician and
clinical services, other professional services (specialists), dental services, home health
care, nursing care facilities, medical equipment, prescription drugs, and various other
services and products.1 Hospital-based care comprised 33% of health spending (the
largest percentage), whereas physician and clinical services made up 20%, and other
health and personal care services totaled 5%, with the other groups (excluding
prescription drugs) comprising the remainder.1 Prescription drugs dispensed through
retail pharmacies accounted for roughly 10% of the $3.5 trillion dollars spent on the
total population for healthcare in 2017;1 and expenditures on cancer treatments are
expected to increase over time as new drugs tend to be more expensive than current
standards of care.11

With prescription drugs comprising a significant portion of cancer-related
expenditures, this study was conducted to examine the association between the
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number of medications prescribed and healthcare expenditures among cancer
survivors. The objective of this study was to expand current knowledge by examining
the relationship between polypharmacy and direct healthcare expenditures.
Quantifying the relationship between polypharmacy and healthcare expenditure in
cancer is a requisite first step to understand the need for further study in determining
to what degree increased healthcare expenditure is attributable to medication-related
adverse events, or if polypharmacy is merely a proxy for burden of illness.
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2.3 Methods

Study design and data source
We used a multi-year cross-sectional study design and utilized the Medical
Expenditures Panel Survey (MEPS) database, a publicly available de-identified
nationally representative database of the US.12 The MEPS is a set of surveys
containing nationally representative non-institutionalized persons, households
(families and individuals), their medical providers, and employers throughout the US
since 1996.12 The MEPS uses a 2-year, 5-panel overlapping survey design of
interviews.

We first used the medical conditions file to find individuals who reported
cancer by using the cancer specific diagnosis codes through the Agency for Healthcare
Research and Quality (AHRQ) clinical classification code system (Appendix A). We
then linked the medical conditions, prescribed drugs, and household data files through
a unique identifier for each individual cancer survivor.12 We also used these clinical
classification codes and the ICD-9-CM codes to identify concurrent chronic conditions
using AHRQ’s Elixhauser comorbidity codes.13 Further details regarding the MEPS
have been described elsewhere.12

Sample selection
The analytic sample included cancer survivors who were defined as adults (≥
18 years old) with cancer who (1) responded ‘Yes’ to the MEPS survey question:
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“Have you ever been told by a doctor or other health professional that you had cancer
or a malignancy of any kind?”; and (2) were alive at the end of the reference panel
year. For our analyses we pooled data from years 2008, 2010, 2012, and 2014. In the
MEPS, individuals are followed for two years, so to avoid including repeated
observations we selected even years only. We excluded people with zero person-level
sample weights and survivors with nonmelanoma skin cancer because treatment for
basal and squamous cell carcinomas are often non-invasive compared to melanoma.
Individuals also were excluded if they had more than one type of cancer due to the
inability to determine an association between the person’s total expenditures and one
cancer type. Men with breast cancer were excluded because of small sample size and
lack of generalizability to female breast cancer survivors. People under the age of 18,
with missing age information, had an age at diagnosis greater than their reported age,
or who died during the panel year were excluded. Figure 1 shows a flowchart of
inclusion and exclusion criteria.

Measures
Dependent variable: Direct healthcare expenditures
Mean annual direct healthcare expenditures incurred per US cancer survivor
was the dependent variable of interest. The expenditures represent the total direct
payments from all reported sources to hospitals (facility and separately billed
physicians), physicians, other medical, home health providers, for other providers, for
dental providers, for miscellaneous expenses, and for prescriptions (Appendix C).14
We created 5 distinct categories for expenditures: hospital, office-based, emergency
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room, prescriptions, and other medical expenses. Hospital expenditures were the
summation of the expenditures from the hospital outpatient visits and inpatient stays.
Other medical expenditures included dental visits, home health providers (agency
sponsored and paid independent provider), vision, and other medical expenses. Officebased, emergency room, and prescription expenditures were standalone categories
within the MEPS. These expenditure groupings, when summed, equaled that of the
total direct annual healthcare expenditures per cancer survivor.

Key independent variable
Polypharmacy (PP)
The MEPS include a prescriptions file with therapeutic medication class
information which are linked to the Multum Lexicon database for analysis.15 We used
these therapeutic class details to determine the maximum number of distinct classes of
prescription medications the individuals were on in one of the panels that coincided
with our study years. A consensus definition of PP does not currently exist; however,
the most common definition in the literature is 5 or more concomitant medications.8
We chose 5 or more classes of medications as our definition for PP based on our
review of the literature which included several studies which used classification
classes.16,17

Other independent variables
Demographic variables included age group, sex, race/ethnicity, US geographic
region (Northeast, South, Midwest, and West), and marital status (married or not
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married). Socioeconomic variables included income (low, middle, high based on
poverty level), insurance status (privately-, publicly-, or uninsured), and level of
education (did not graduate high school, graduated but did not attend college, and at
least some college level education). Time since cancer diagnosis was calculated by
subtracting age at diagnosis, a variable included in the MEPS, from the patient’s
reported age. For patients who could not remember their age at diagnosis or was
otherwise missing from the dataset, 51.7% total missingness, multiple imputation was
used to fill in these missing values. We used the fully conditional specification (FCS)
method, with all variables in the model creating 40 imputed data sets.18 These data sets
were then combined to get mean estimates across all variables.

Clinical variables included type of cancer, Elixhauser comorbidity score, and
number of total provider encounters. Cancer type was grouped in the following
manner: breast, prostate and other male genital (included testicular cancer), cervical
and other female genital (included uterine, ovarian, other female cancers), colon and
other gastrointestinal (GI) (stomach, liver, pancreas, and other GI cancers), melanoma,
leukemias/lymphomas and other/unspecified (included lung). Lung cancer was
grouped into the “other/unspecified” group due to small sample size. We used the
Elixhauser comorbidity score to assess physical and mental diseases and disorders due
to its well-established validity. The Elixhauser comorbidity score is the summation of
approximately 31 comorbid conditions, which are first dichotomized as being present
or absent in the patient, which we then categorized based on its distribution using
quartiles to 0, 1, 2 or ≥ 3 (Appendix D).13 Survivors with both complicated and
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uncomplicated diabetes or hypertension diagnoses were assumed to have the
complicated, more severe, state of disease for these analyses. Provider encounters
were defined as total provider or outpatient visits obtained from the household files
and categorized into 0-4, 5-9, 10-19, and ≥ 20 visits based on quartiles.

Statistical analysis
Significant differences in per-person mean annual direct expenditures between
cancer survivors with and without PP were assessed using t-tests and analysis of
variance (ANOVA), stratifying by type of cancer. Due to the positively skewed nature
of the expenditures, a natural logarithm transformation was used to normalize the
dependent variable. To fit a valid model for the log transformed expenditures we
excluded patients with zero expenditures (n=28). A subgroup-specific smearing factor
was applied after retransformation (exponentiation of beta estimate) to approximate
nominal dollar values because without the smearing factor the estimates would be
biased toward $0.19 Expenditures were adjusted for inflation to 2017 US dollars using
the Bureau of Labor Statistics consumer price index for medical care services.20

The primary analysis was to estimate the association between PP and total
healthcare expenditures. Potential covariates were assessed in univariate OLS models
for their statistical significance. If a variable was significantly associated with both PP
and healthcare expenditures (F test p-value <0.10) it was included for assessment in a
multivariable ordinary least squares (OLS) model. Multivariable (OLS) regression
models were used to assess the relationship between PP and healthcare expenditures
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while controlling for significant covariates. An iterative process was used to include
individual covariates one at a time into the multivariable OLS model based on its F
test p-value. If a covariate was insignificant after placement into the model it was
removed, and the model was run again with the next covariate, until no more
significant covariates remained for analysis.

In a secondary analysis, the relationships between PP and healthcare
expenditures were modeled by setting of care overall, and by setting of care and type
of cancer. Separate models were created for each of the log expenditures from the 5
settings of care as the dependent variables, controlling for all significant covariates
from the primary analysis. OLS regression was used to analyze mean expenditures by
PP for each setting overall. To estimate the mean expenditures for a woman with
breast cancer, we first created a cohort of women with breast cancer, then we
separately modeled the per-patient mean expenditures with each setting as a dependent
variable. OLS regressions were used to find mean differences in expenditures by PP in
both secondary analyses.

Due to the complexity of the survey design used in the MEPS; stratification,
clustering, and weighting were performed. Significance tests were all performed at the
α = 0.05 level. Analyses were conducted using SAS version 9.4 (SAS Institute, Cary,
NC).
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2.4 Results

The study population consisted of 3,435 (N= 10,580,285 weighted) adult
cancer survivors (Figure 1, Table 1). The three most prevalent types of cancer were
female breast (17.2%), prostate (14.0%, and melanoma (7.0%) (Table 1). Of these,
1,523 (N= 4,649,586 weighted, 43.9%) adults reported use of 5 or more therapeutic
classes of prescribed medications. Older survivors (≥75 years) were most likely
(60.8%) to have PP; while the youngest survivors (18-49 years) were least likely to
have PP (18.4%). Most cancer survivors (54.0%) had at least 2 comorbid conditions,
with over one-third (34.2%) having at least 3. Weighted percentages for all other
demographic, socioeconomic, and clinical variables categorized as with or without
polypharmacy are included in Table 2.

PP and prescription medication utilization
There were approximately 55 million (weighted) prescribed medications per
year for the total cohort of cancer survivors: 72.5% (40.1 million (M)) of these
prescriptions were to respondents defined as having PP (not shown). Those without PP
were on 90 distinct therapeutic classes compared to 93 for those with PP. Of those
therapeutic classes, 92.6% (88/95) were not unique between those without PP and
those with PP. Antihyperlipidemic medications comprised the most commonly
prescribed chronically used therapeutic class for both those with (7.0%; 2.8M
weighted prescriptions) or without (9.2%; 1.4M) PP. Beta-adrenergic blocking agents
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were the second most prevalent therapeutic class in those with PP (4.5%; 1.8M) (Table
3).

Overall expenditure differences by PP
The unadjusted and untransformed mean per-patient direct healthcare
expenditures for the overall study cohort was $15,369 (95% CI: $14,146-$16,591).
The total per year expenditures averaged $162.6 billion, adjusted to 2017 dollars.
Those with PP accounted for 70.3% of the total annual mean expenditures. The total
annual mean expenditures were $21,652 (95% CI: $18,485-$24,820) for those with PP
and $13,414 (95% CI: $9,952-$16,875) for those without PP, resulting in a
significantly different (p-value <.0001) mean difference of $8,239 (Table 4).

Total mean annual expenditures by setting of care and PP
Mean annual adjusted expenditure in the hospital setting was the largest
contributor to total annual expenditures for cancer survivors (Figure 2). Expenditures
for cancer survivors in the hospital setting amounted to $68.8 billion (B) (standard
deviation: SD $22.9B) annually and comprised 42.3% of total spend by setting.
Hospital-based expenditures accounted for 42.0% ($21.9B SD $9.7B) of $52.1B (SD
$13.8B) total annual expenditures for cancer survivors without PP. For those with PP,
hospital-based expenditures comprised 42.5% ($47.0B SD $21.3B) of $110.5B (SD
$28.2B) total expenditures per year. Prescription medicines for all cancer survivors
made up 19.9% ($32.3B SD $6.7B) of total annual expenditures. For survivors with
PP, prescriptions made up 76.5% ($24.7B SD $5.1B) of total annual expenditures
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compared to 23.5% ($7.6B) for those without PP. Other medical expenditures totaled
8.6% ($14.0B SD $7.4B) of total annual expenditures by setting. Survivors with PP
accounted for 71.4% ($10.0B SD $7.4B) of other medical expenditures. Emergency
room expenditure accounted for 2.3% ($3.7B SD $2.1B) and was the smallest
contributor to total annual mean expenditures in both those with polypharmacy and
those without PP (2.3% ($2.6B SD $1.9B) and 2.2% ($1.1B SD $527M),
respectively).

Expenditure differences by setting of care and PP
Table 4 shows the smear-adjusted log transformed mean expenditures for each
setting of care by PP. Mean expenditures were higher for each setting, except for
office-based visits, with the highest average mean expenditures being spent in the
hospital setting for those with PP ($12,314 95% CI: $9,981-$15,040). However,
differences in mean expenditures by PP for both office-based ($2,350 CI: 2,126$2,571 vs. $2,410 CI: $2,203-$2,637 p-value 0.3146) and emergency room ($2,444
CI: $2,021-2,927 vs. $1,598 CI: $1,308-$1,952 p-value 0.0921) settings were not
significantly different than for those without PP.

Expenditure differences by type of cancer, setting of care, and PP
Figure 3 presents the results from smear-adjusted OLS analyses of mean
transformed expenditures by settings of care and type of cancer by PP status, which
controlled for significant variables. Across all types of cancer, except for melanoma
($7,709 vs. $16,922, p-value 0.4739), expenditures in the hospital setting for survivors
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with PP were higher than for those without PP. However, only leukemias &
lymphomas and other/unspecified cancer types were significantly higher in those with
PP than without PP ($19,114 vs. $8,742 p-value 0.0048 and $12,964 vs.8,943 p-value
0.0073, respectively). For office-based care, mean expenditure differences were
significantly higher in those with PP for only the other/unspecified cancer type
($2,296 vs. $2,069 p-value 0.0206). Emergency room mean differences for
expenditures were significantly higher in survivors with PP and leukemias and
lymphomas ($2,437 vs. $641, p-value 0.0067), melanoma ($765 vs. $403, p-value
<.0001), and the other/unspecified cancer categories ($3,330 vs. $1,689, p-value
0.0471). Mean expenditures differences between the other medical category were
significantly different for breast cancer ($2,242 vs. $1,036 p-value 0.0088) and
colorectal ($4,955 vs. 1,505 p-value .0243). For each type of cancer, the modeled
values for prescription medication expenditures were significantly higher (p-value
<0.0001) in all survivors with PP compared to those without PP.

Associations between PP and healthcare expenditures
As seen in Table 5, PP was significantly associated with higher total annual
mean log expenditures (β= 0.60, SE=0.05, p-value <.0001) when controlling for all
significant variables (age, insurance, cancer type, comorbidity, provider encounters,
and time since cancer diagnosis). This estimate represents an 82% increase in the total
annual mean log expenditures due to a one-unit increase of the average number of
cancer survivors having PP, holding all other variables at their reference class.
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Several covariates had significant differences from their referent group in their
association with total annual mean expenditures. All types of cancer examined, except
for cervical and other female genital cancers, were significantly different from
melanoma in their association with log expenditures while controlling for PP, age,
insurance, time since cancer diagnosis, comorbidity, and provider encounters (Table
5). Colon and other GI cancers was the most significantly different (β= 0.57, SE 0.11,
p-value <.0001) from melanoma (reference group) with a 76% increase in mean log
expenditures. Survivors with ≥ 3 comorbid conditions had a significant 37% increase
from those without any comorbidities (β= 0.31, SE 0.06, p-value= <.0001). Survivors
with public insurance (β= -0.12, SE 0.04, p-value= 0.0023) and without any insurance
(β= -0.42, SE 0.14, p-value= 0.0029) were associated with lower mean log
expenditures than survivors with private insurance (12% and 34%, respectively).
Those aged 50-64 were significantly different from their referent group of 18-49 years
(β= 0.19, SE 0.06, p-value= 0.0014) with an associated 20% increase in mean log
expenditures. Lastly, the number of visits to a provider was progressively significant
and by far the most associated with increased mean log expenditures, with ≥ 20
encounters having a 540% increase in mean log expenditures (β= 1.85, SE 0.08, pvalue <.0001) (Table 5). Time since cancer diagnosis of 2 years or less was
significantly different in mean log expenditures compared to cancer survivors of 3 to 5
years by an increase of 36% (β= 0.31, SE 0.08, p-value <.0001).

After applying the subgroup-specific smear factors to the retransformed
(exponentiated) estimates of the adjusted mean expenditures, the annual expenditure
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for someone with PP was $13,226 (SD $3,766), which was $4,513 more than
survivors without PP at $8,753 (SD $5,082), and was significant (p-value <.0001).
The log expenditure estimates, subgroup-specific smearing factors, and final adjusted
values are presented in Table 6.
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2.5 Discussion

In this study, we found that approximately 44 of 100 adult cancer survivors per
year were defined as having PP. PP was associated with significantly higher mean
annual direct healthcare expenditures in all analyses, including unadjusted, adjusted,
and our log transformed multivariable OLS model. Unadjusted total mean
expenditures for cancer survivors in our study were higher than the 2012 estimated
expenditures reported by AHRQ for the general population by 89% ($15,369 vs.
$8,125, respectively).21 For survivors with PP, the unadjusted difference in mean
expenditures was associated with an increase of 70% in spending, with annual spend
equaling $21,652 compared to $13,414 for survivors without PP. In the adjusted
analysis, PP was associated with a significant 82% increase in the estimated log
expenditures compared to those without PP.

By comparing the various settings of care for cancer survivors, we found that
spending in the hospital setting is higher compared to the other settings, for both those
with and without PP, which aligns with prior research.1 Hospitalization has been
linked to increased medication use in older cancer patients.9,22 However, hospitalbased expenditures for those both with or without PP were approximately 42% of
spend by setting, higher than that in the general population (33%).1 The largest
differences for cancer survivors with versus without PP by setting were office-based
(23.7% vs. 33.7%, respectively) and prescription medications (22.4% vs. 14.6%,
respectively). These amounts were also higher as a proportion of spending by setting
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compared to the general population (20% for office-based and 10% for prescription
medication).1 We combined expenditures from both inpatient and outpatient hospital
visits while other studies have categorized hospital costs based solely on inpatient
hospitalizations versus ambulatory (outpatient) hospital visits and office-based visits.23
This may be why hospital-based expenditures were so much higher than office-based
visits in this study. Our analysis provides further evidence that cancer survivors have
substantially greater direct healthcare expenditures than the general population.

Differences existed among the different types of cancers, regarding overall
healthcare expenditures for those with PP compared to those without PP. In the
adjusted analyses, where we controlled for all significant variables, total annual mean
expenditures for those with colon or other GI cancers were the highest, although not
statistically significant from other cancer types. In a 2016 study of the economic
burden (defined as annual medical expenditures plus annual productivity losses) of
colorectal, female breast, and prostate cancer survivors in the US, which also used the
MEPS (years 2008-2012), colorectal cancer was associated with the highest annual
expenditures and productivity losses of the three cancer types.23

Various risk factors for PP among cancer patients include comorbid conditions,
hospitalization, and unnecessary prescribing.9 Most cancer survivors in the current
study had at least 2 comorbid conditions. When examined closer by PP, 6% of those
without a chronic condition were defined as having PP; while 78.2% of those with ≥ 3
conditions had PP. In the log transformed expenditure model, having ≥3 comorbid
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conditions was associated with a 37% increase in expenditures compared to not having
any comorbid conditions. Due to the cross-sectional study design, we cannot
determine causality, but there was a clear association between PP and expenditures.
Future research that focuses on the examination of individual comorbid conditions and
the number of prescriptions an individual are on both pre- and post- cancer diagnosis
would elucidate this relationship further, as it was not the emphasis of this research.

We identified one paper that examined healthcare expenditure differences
among cancer survivors with PP, in which they estimated median prescription
expenditures as $1,633 vs. $784 in noncancer controls, but did not analyze total
expenditure values.10 Knowing that prescription costs significantly differ among
cancer survivors with PP, as well as noncancer counterparts with PP, is important for
addressing disparities among cancer survivors with and without PP. One reason for the
disparities is that spending on anticancer medications doubled from 2012-2017 to
almost $50 billion, with all oncology drugs launched in 2017 having list prices above
$100,000.24 In the US, the cancer drug market is expected to grow 12-15% annually
by 2020, up to $100 billion.24 This growth is expected to be driven by new launches
and increased uptake of existing branded oncologics.24 However, one positive trend is
that oncology drug prices have risen at a slower rate (4.7%-6.4%) on average than that
of the general branded market (6.9%) from 2012-2017.24 We chose to incorporate total
healthcare expenditures by PP among cancer survivors to see differences at the person
and societal levels. In so doing, we hope that policymakers could be informed about
how influential PP is on the healthcare system in the US.
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This study determined that the total annual expenditure estimates for US
cancer survivors for the period of 2008-2014, adjusted to 2017 dollars was $162.6
billion. According to research which used SEER-Medicare data, the estimated costs of
cancer care will equal $157.8 billion by 2020.25 However, when taking into
consideration the declining incidence for most cancers, improving survival rates, and
increasing costs, the authors estimated the total cost could amount to $172.8 billion.25
Our estimate concurs with this as it is in the upper range of these two estimates.

Increased healthcare costs can have negative effects on both the individual
cancer survivor and society as a whole.26 For cancer survivors, concerns over
outcomes previously linked to PP include adverse drug events, drug-drug interactions,
increased morbidity, decreased survival, frailty/disability, and poor medication
adherence.9 On the societal level, policymakers may have to address the increased
expenditures related to prevention initiatives and various adverse health-related
outcomes in this expanding vulnerable population. PP may cause increased healthcare
expenditures because of additional therapeutic monitoring, lab tests, physician office
visits, and follow-up care planning.

Currently in the US, the focus of various advocacy and governmental groups
focuses on lowering the cost of prescription medications. Although this is certainly
needed, for cancer survivors whom are mostly covered by private or public insurances,
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a closer look at hospital and office-based expenditures should also be highly
scrutinized due to the largest proportions of expenditures being spent in those areas.
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2.6 Limitations

As this was a cross-sectional study design, no claim of causality can be made.
Other limitations may exist due to the way the data was collected, through
computerized survey. Recall bias may have impacted the answers to the survey as
some respondents may not have an accurate recollection of life events due to various
reasons (e.g. older age, responding for another household member). The MEPS uses a
3-digit coding system for ICD-9-CM codes, and thus the nuances of certain comorbid
conditions may not be recorded. Likewise, using the Elixhauser comorbidity score
dichotomizes conditions and does not consider differences in severity of comorbid
conditions. No severity or stage of cancer for the survivors is recorded which would
otherwise explain large differences in expenditures of survivors of the same type of
cancer. For this analysis, based on sample sizes of individual cancers, we grouped
various cancers together which may obfuscate more precise expenditure differences
among those survivors.
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2.7 Conclusion

Mean total annual expenditures for cancer survivors with PP was significantly
higher than for those without PP, with significant differences attributable to setting of
care, intensity of utilization, and type of cancer. Understanding this association is the
first step to addressing the underlying causes of expenditure differences among those
cancer survivors with versus without PP.
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Figure 1. Selection of Patients for Analyses of Prevalence of Polypharmacy in Adult Cancer
Survivors (≥ 18 years) (2008, 2010, 2012, 2014), Unweighted.
5,664 All patients who self-reported
being diagnosed with cancer 2008,
2010, 2012, 2014
113 (2.0%) Excluded patients with
zero person-weight information.
5,551 (98.0%) All cancer patients
with a valid person weight
1,844 (33.2%) Excluded patients
with nonmelanoma skin cancer
(1,183; 21.3%) or more than one type
of cancer diagnosis (659; 11.9%);
men with breast cancer (2; <0.1%).

3,707 (65.5%) All valid cancer
patients of interest

272 (7.3%) Excluded patients who
had $0 total expenditure value (28;
0.7%), missing age (112; 3.0%), < 18
years (70; 1.9%), died in round (61;
1.6%), or age at diagnosis was >
current age (1; <0.1%).

3,435 (60.6%) Adult Cancer
Survivors in Study Sample

1,912 (55.7%)
No Polypharmacy

1,523 (44.3%)
Polypharmacy
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Table 1. Distribution of Cancer Diagnoses in Adult Cancer Survivors (≥ 18 years) (2008, 2010,
2012, 2014) of Interest Available in MEPS.
Type of Cancer
Breast
Prostate and other male genital
Cervical and other female genital
Colon and other GI
Melanoma
Leukemias and lymphomas
Other / unspecified
Total

N (%), unweighted
613 (17.2%)
484 (14.0%)
228 (5.7%)
250 (6.4%)
193 (7.0%)
160 (4.7%)
1,507 (45.0%)
3,435 (100.0%)

68

N, weighted
1,820,759
1,486,297
607,562
673,767
741,584
493,481
4,756,835
10,580,285

Table 2. Demographic and Clinical Characteristics of Adult Cancer Survivors (≥ 18 years) with
Cancer Diagnoses of Interest during 2008, 2010, 2012, 2014, by Polypharmacy Status (N=
10,580,285).
Demographic and Clinical
Characteristics of Cancer
Survivors
Age group (years)a
18-49
50-64
65-74
≥ 75
Sex
Men
Women
Race/ethnicity
White
African American
Hispanic
Other
Region
Northeast
Midwest
South
West
Provider Encounters
≤4
5-9
10 - 19
≥ 20
Marital Status
Married
Not Married
Education Level
Less than High School
High School
Some College
Income Levelb
Low
Medium
High
Insurance Coverage
Private
Public
Uninsured
Type of Cancerc
Breast
Prostate/other male genital
Cervical/other female genital
Colon/other gastrointestinal
Melanoma
Leukemias and lymphomas
Other/unspecified
Time since cancer diagnosis
(years)
0-2
3-5
6-10
> 10

No Polypharmacy

Polypharmacy

(N= 5,930,699 | 56.1%)

(N= 4,649,586 | 43.9%)

1,746,353 (81.6%)
2,019,881 (60.3%)
1,222,852 (45.5%)
941,613 (39.2%)

393,978 (18.4%)
1,327,615 (39.7%)
1,467,364 (54.5%)
1,460,629 (60.8%)

2,619,191 (55.8%)
3,311,508 (56.2%)

2,073,216 (44.2%)
2,576,370 (43.8%)

4,819,924 (55.8%)
415,971 (50.4%)
429,810 (63.6%)
264,994 (60.9%)

3,824,725 (44.2%)
409,089 (49.6%)
245,621 (36.4%)
170,151 (39.1%)

1,232,839 (57.7%)
1,224,135 (52.8%)
2,002,800 (53.1%)
1,470,925 (62.6%)

904,430 (42.3%)
1,096,576 (47.2%)
1,770,205 (46.9%)
878,375 (37.4%)

1,914,471 (81.6%)
1,773,239 (64.9%)
1,407,070 (48.0%)
835,919 (32.5%)

432,042 (18.4%)
957,942 (35.1%)
1,524,128 (52.0%)
1,735,474 (67.5%)

3,723,611 (58.0%)
2,207,088 (53.0%)

2,694,351 (42.0%)
1,955,235 (47.0%)

2,661,512 (52.9%)
943,463 (50.6%)
2,325,724 (63.2%)

2,374,522 (47.1%)
920,694 (49.4%)
1,354,370 (36.8%)

1,378,526 (46.4%)
1,555,858 (55.4%)
2,996,315 (62.4%)

1,593,485 (53.6%)
1,250,218 (44.6%)
1,805,883 (37.6%)

4,428,221 (59.9%)
1,179,479 (42.0%)
322,999 (84.5%)

2,958,484 (40.1%)
1,631,759 (58.0%)
59,343 (15.5%)

946,815 (52.0%)
787,573 (53.0%)
377,641 (62.2%)
338,687 (50.3%)
448,397 (60.4%)
255,124 (51.7%)
2,776,462 (58.4%)

873,945 (48.0%)
698,724 (47.0%)
229,921 (37.8%)
335,080 (49.7%)
293,187 (39.6%)
238,358 (48.3%)
1,980,371 (41.6%)

p-value
<.0001

0.8300

0.0109

0.0158

<.0001

0.0168

<.0001

<.0001

<.0001

0.0597

0.0014
1,056,198 (58.2%)
1,071,483 (58.1%)
1,964,487 (58.3%)
1,838,531 (51.8%)
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759,676 (41.8%)
773,356 (41.9%)
1,404,582 (41.7%)
1,711,972 (48.2%)

Elixhauser Comorbidityd
<.0001
0
2,209,455 (94.9%)
118,926 (5.1%)
1
1,921,954 (75.6%)
621,467 (24.4%)
2
1,010,014 (48.3%)
1,083,265 (51.7%)
≥3
789,276 (21.8%)
2,825,929 (78.2%)
Notes: aThe Medical Expenditures Panel Survey sets an upper limit of 85 years old.
bIncome level: low (<200% above poverty line), medium (200% to 400% above poverty line), high (>400%
above the poverty line).
cType of cancer included the following categorizations: prostate (included testicular cancer and cancer of
other male genitals), cervical (included uterine, ovarian, other female cancers), colorectal (esophageal,
stomach, colon, rectum and anus, liver and intrahepatic bile duct, pancreas, and other gastrointestinal cancers).
dElixhauser Comorbidity Score: The summation of a binary variable (Present/Absent) for each of the
comorbid conditions in the group of conditions (Appendix D).
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Table 3. Top 10 Most Frequently Prescribed Therapeutic Classes among Patients with and
without Polypharmacy, in US Adult Cancer Survivors (≥ 18 years) for 2008, 2010, 2012, 2014
(N=10,580,285) weighted n, %.
No Polypharmacy
Therapeutic Class

Rx (n)

Antihyperlipidemic
Agents
Thyroid Hormones

Polypharmacy
Therapeutic Class

Rx (n)

1,395,299

Rx
(%)
9.2%

Antihyperlipidemic Agents

2,809,821

Rx
(%)
7.0%

693,981

4.6%

1,794,952

4.5%

Antidepressants

680,754

4.5%

Beta-Adrenergic Blocking
Agents
Antidepressants

1,607,836

4.0%

Beta-Adrenergic
Blocking Agents
Angiotensin Converting
Enzyme Inhibitors
Dermatological Agents

548,796

3.6%

1,608,534

4.0%

524,150

3.4%

Angiotensin Converting
Enzyme Inhibitors
Proton Pump Inhibitors

1,558,512

3.9%

519,554

3.4%

Diuretics

1,461,365

3.6%

Proton Pump Inhibitors

503,199

3.3%

Antidiabetic Agents

1,421,401

3.5%

Antihypertensive
Combinations
Antidiabetic Agents

459,858

3.0%

Anticonvulsants

1,264,175

3.2%

415,267

2.7%

Thyroid Hormones

1,132,490

2.8%

Diuretics

408,366

2.7%

Bronchodilators

914,132

2.3%

Notes: Rx(n) = Total weighted number of prescribed therapeutic classes to cancer survivors on
average for the years 2008, 2010, 2012, 2014. Rx(%) = Average annual number of prescribed
therapeutic classes as a weighted percentage of total average annual by polypharmacy.
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Figure 2. Expenditures Among US Adult Cancer Survivors (≥ 18 years) by Setting of Care and
Polypharmacy for 2008, 2010, 2012, 2014, (%).
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Table 4. Adjusted Mean Annual Total Expenditures by Setting of Care and Polypharmacy, in US
Adult Cancer Survivors (≥ 18 years) for 2008, 2010, 2012, 2014 (N=10,580,285), Weighted ($US)
Settings of Care

Mean (95% CI), $US
No Polypharmacy

Polypharmacy

Hospital

9,398 (7,542 - 11,829)

12,314 (9,981 - 15,040)

0.0018

Mean
Difference
($)
2,915

Prescriptions

1,709 (1,531 - 1,908)

4,056 (3,707 - 4,483)

<.0001

2,347

Office-based

2,410 (2,203 - 2,637)

2,350 (2,126 - 2,571)

0.3146

(60)

Other medical

1,127 (1,030 - 1,233)

2,447 (2,192 - 2,759)

<.0001

1,320

Emergency room

1,598 (1,308 - 1,952)

2,444 (2,021 - 2,927)

0.0921

846

p-value

Notes: Values are adjusted variables significantly associated with log expenditures and may include a
combination of any of the following variables: age group, gender, race, region, number of provider encounters,
marital status, comorbidity score, education level, poverty level, and insurance coverage.
*Values are rounded to nearest whole dollar value or percent where applicable.
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Figure 3. Results of Ordinary Least Squares Regression Describing Adjusted Mean Log
Expenditures for Each Type of Cancer among US Adult Cancer Survivors (≥ 18 years) by Setting
of Care and Polypharmacy for 2008, 2010, 2012, 2014 (N=10,580,285), ($US)
$35,000

Hospital

Office-based

Prescriptions

Other medical

Emergency room

$32,339

$31,087

$30,000
$26,879
$25,104

$25,000
$21,547

$21,432
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$18,473
$16,007 $16,300

$15,853

$15,541

$15,352

$15,000

$13,275

$12,851

$10,000

$5,000

$0
No PP

PP

Breast
(female)

No PP

PP

Prostate &
other male

No PP

Cervical &
other female

Breast
Setting
Hospital
Office-based
Prescriptions
Other medical
Emergency room

No PP
5,971
2,353
1,815
1,036
1,676

PP

No PP

PP

Colon &
other GI

Prostate
PP
6,390
2,339
3,673*
2,242*
1,363

Melanoma

No PP
7,294
2,937
2,038
1,294
2,737

PP
11,675
2,127
3,486*
1,854
2,405

No PP

PP

No PP

PP

No PP

PP

Melanoma Leukemias & Other &
lymphomas unspecified

Cervical
No PP
7,058
2,441
1,016
1,238
1,522

Leukemia/Lymphoma

PP
18,839
2,249
3,041*
1,015
1,735

Colon
No PP
10,543
3,503
1,786
1,505
1,136

PP
17,273
2,844
6,249*
4,955*
1,018

Other

No PP
16,922
2,725
887

PP
7,709
2,837
3,663*

No PP
8,742
4,016
852

PP
19,144*
3,605
2,313 *

No PP
8,943
2,296*
1,463

PP
12,964*
2,069
4,178*

492
406

879
765 *

1,101
641

3,678
2,347*

1,150
1,689

2,563
3,330*

Note: No PP = no polypharmacy; PP = polypharmacy. Hospital = inpatient or outpatient hospital-based
expenditure. Emergency = Emergency Room. Prescriptions = prescription medications. Other medical =
sum of spending for the following: dental care, vision care, home health agency (sponsored and paid
independent providers), and other expenses not classified elsewhere. Estimates are adjusted for the
following variables: age group, gender, race, region, number of provider encounters, marital status,
comorbidity score, education level, poverty level, and insurance coverage. Gender was excluded from
cervical, prostate, and breast cancer models. *= significantly increased expenditures compared within
PP / No PP pairing at alpha = 0.05 significance.
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Table 5. Unadjusted and Adjusted Regression Estimates (β) with Standard Errors (SE) of
Significantly Associated Variables Based on an Ordinary Least Squares Regression Model with
Log Transformed Expenditures for Patient and Clinical Factors in US Adult Cancer Survivors (≥
18 years) for 2008, 2010, 2012, 2014 (N=10,580,285).
Studied Variables

Unadjusted Model
Beta (SE)
P value

Adjusted Model
Beta (SE)
Change P value
(%)

Polypharmacy
1.23 (0.04)
<.0001
0.60 (0.05)
82.0
<.0001
Yes
Age Group (years)
Reference
18-49
0.65 (0.08)
<.0001
20.4
0.0014
50-64
0.19 (0.06)
0.77
(0.08)
<.0001
4.6
0.4834
65-74
0.04 (0.06)
0.87 (0.08)
<.0001
8.7
0.2587
≥ 75
0.08 (0.07)
Insurance Coverage
Reference
Private
0.07 (0.06)
0.2467 -0.12 (0.04)
-11.6
0.0023
Public
-1.15 (0.17)
<.0001 -0.42 (0.14)
-34.3
0.0029
Uninsured
a
Type of Cancer
0.41 (0.12)
0.0008
0.20 (0.09)
21.8
0.0034
Breast
0.06 (0.16)
0.6948
0.21 (0.11)
23.4
0.0518
Cervical/other female genital
0.71
(0.15)
<.0001
0.57
(0.11)
76.3
<.0001
Colon/other gastrointestinal
0.53 (0.18)
0.0033
0.40 (0.13)
48.7
0.0015
Leukemias and lymphomas
0.20 (0.12)
0.0834
0.21 (0.09)
23.9
0.0135
Other/unspecified
0.34
(0.12)
0.0057
0.27
(0.10)
31.1
0.0070
Prostate/other male genital
Reference
Melanoma
Elixhauser Comorbidity Index (no. of conditions)
Reference
0/None
0.54 (0.08)
<.0001
0.10 (0.06)
11.0
0.1014
1
0.83 (0.08)
<.0001
0.14 (0.07)
15.2
0.0441
2
1.38
(0.07)
<.0001
0.31
(0.06)
36.8
<.0001
≥3
Provider Encounters (no. of visits)
Reference
0-4
0.84 (0.07)
<.0001
0.68 (0.07)
99.6
<.0001
5-9
1.54 (0.07)
<.0001
1.23 (0.07)
247.8
<.0001
10 - 19
2.30 (0.07)
<.0001
1.85 (0.08)
547.1
<.0001
≥ 20
Time since cancer diagnosis (years)
0.35 (0.08)
<.0001
0.31 (0.08)
35.7
<.0001
0-2
3-5
Reference
0.07 (0.06)
0.2299
0.06 (0.07)
6.6
0.3618
6-10
0.11
(0.05)
0.0287
0.03
(0.07)
2.9
0.6793
>10
a
Notes: Type of cancer included the following categorizations: prostate (included testicular cancer
and cancer of other male genitals), cervical (included uterine, ovarian, other female cancers),
colorectal (esophageal, stomach, colon, rectum and anus, liver and intrahepatic bile duct, pancreas,
and other gastrointestinal cancers). Adjusted R2 value for final model equaled 0.46. Model intercept
equaled 7.05 (SE=0.12).
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Table 6. Subgroup-Specific Smear Adjusted Mean Annual Direct Healthcare Expenditures, with
or without Polypharmacy, in US Adult Cancer Survivors (≥ 18 years) for 2008, 2010, 2012, 2014
(N=10,580,285).
Log
Smear
Retransformed
SubgroupTransformed
Adjusted
Standard
Expenditure
Specific
Polypharmacy
Expenditure
Expenditure
Error
Estimate (expβ,
Smearing
Estimate
Estimate,
$US)
Factor
(ln(β))
($US)
No
8.3930
0.05151
4,416
1.98199
8,753
Yes
8.9916
0.05626
8,035
1.65097
13,266
Note: Adjusted R2 value for final OLS model was 0.46. Mean differences of log transformed
expenditure estimates was significant (p<.0001). The subgroup-specific smearing factors were
calculated as the mean of the exponentiated residuals. Smear-adjusted expenditure estimate is the
product of the retransformed expenditure estimate and the subgroup-specific smearing factor.
Adjusted for age, type of cancer, insurance coverage, comorbidity score, time since cancer diagnosis,
and number of provider encounters.
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3.1 Abstract

BACKGROUND: Patients with cancer are particularly susceptible to polypharmacy
(PP), which may increase the risk of developing health complications (HCs). The
objective of this study was to evaluate the association between PP and nonfatal HCs
among newly diagnosed patients with common cancer types in the United States (US).
METHODS: We conducted a retrospective cohort study of de-identified, newly
diagnosed adult (≥ 18 years old) breast, prostate, lung and colorectal cancer patients
using the Optum Clinformatics® DataMart (Optum, Eden Prairie, MN, USA)
administrative claims database, years 2010-2015. PP was defined as ≥ 5 distinct
therapeutic classes of medications filled through an outpatient pharmacy in the first
quarter following patients’ index cancer diagnosis. The dependent variable was
nonfatal HCs (none vs. ≥ 1 event). HCs were grouped by clinically meaningful
category: cardiovascular (CV), central nervous system and psychiatric (CNS),
gastrointestinal (GI), hematologic (HEMA), metabolic (METB), skeletal (SKEL), and
miscellaneous drug-related events (ADE). We used multivariable logistic regression
(LR), with adjusted odds ratios (aORs) with 95% confidence intervals (CI) as the
measure of effect to examine associations between PP and HCs in patients with cancer
overall, and by type of cancer, controlling for demographic and physical and mental
comorbid conditions.
RESULTS: The analytic cohort consisted of 35,336 individuals with cancer (breast
14,700, prostate 15,706, colorectal 3,292, and lung 1,638). PP was present in 14,573
(41.2%) of individuals. Percentage of PP by type of cancer were: breast 42.7%,
prostate 37.0%, colorectal 43.7%, lung 64.0%. Individuals with PP had higher rates of
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HCs compared to those without PP: CV 19.2% vs. 8.9%, CNS 5.2% vs. 2.4%, GI
2.8% vs. 1.6%, HEMA 9.9% vs. 5.5%, METB 3.8% vs. 1.1%, SKEL 5.6% vs. 3.5%,
and ADE 3.0% vs. 1.4%, during follow-up. In the primary analysis, PP was associated
with a 31% increased odds (aOR) of having ≥ 1 HCs, controlling for age, region, type
of cancer, comorbidities, radiation and chemotherapy treatments. PP was significantly
associated with a higher risk of having ≥ 1 HC in each cancer type (aOR: breast 1.37,
95% CI: 1.31-1.42; prostate 1.27, CI: 1.22-1.32; colorectal 1.26, CI: 1.16-1.36; lung
1.25, CI: 1.11-1.40). Active chemotherapy was associated with significantly increased
odds of ≥ 1 HC in colorectal (aOR: 1.35, CI: 1.21-1.50) and lung (aOR: 1.33, CI: 1.151.54) cancers, but not significantly associated with breast or prostate cancers.
CONCLUSIONS: Newly diagnosed patients with breast, prostate, colorectal, or lung
cancer with PP were all at a higher risk of having ≥ 1 nonfatal HCs as compared to
those without PP. Active chemotherapy treatment was associated with increased risk
of HCs in colorectal and lung cancer patients, but not in breast or prostate cancer
patients.
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2.2 Introduction

PP is defined most commonly in the literature as the concomitant use of ≥ 5
medications,1 and one study found that 80% of newly diagnosed elderly (≥ 65 years)
cancer patients met this criterion.2 Patients with cancer often receive many
medications,3 regularly exceeding the numerical threshold for polypharmacy (PP).
Reasons for the multitude of prescribed medications in cancer patients are usually
rooted in underlying chronic conditions occurring naturally with aging.4 For instance,
32.2% of older women (> 66 years) newly treated for breast cancer have
comorbidities.5 With the median ages at diagnosis for the four most common types of
cancer in the United States (US) being 61 years for breast cancer, 68 years for
colorectal cancer, 70 years for lung cancer, and 66 years for prostate cancer, comorbid
conditions are common in this population.6 Comorbid conditions in patients with
cancer can influence the treatment care planning.4 For example, women with breast
cancer may not receive certain types of chemotherapy if comorbid conditions
sufficiently increase the risk of complications.5# However, depending on stage of
cancer and other factors, women may still receive additional medications such as
hormone therapy or pain relievers, in addition to medicines they take for underlying
conditions.

Some cancer patients may, or may not, be using 5 prescribed medications at
the time of their diagnosis. However, during the course of treatment for cancer, they
may add new medications resulting in PP. One concern which arises from PP among
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older patients is the increased risk associated with use of potentially inappropriate
medications (PIMs) that may have a deleterious effect on the patient’s health. PP has
been associated with PIMs previously.7,8,9 PIMs are concerning for cancer patients as
one study found that, of newly diagnosed cancer patients who visited ambulatory
oncology clinics, the odds of using PIMs increased by 18% for each additional
medication in those defined as having PP (≥ 5 concomitant medications) compared to
those without PP.10 Common cancer-related ailments such as pain, emesis, depression,
venous thrombosis, and seizures can also necessitate additional medications.10

The increased use of combinations of medications also increase the risk of
drug-drug interactions (DDIs) among cancer patients, even among those not currently
receiving antineoplastic treatments.1 DDIs can result in a lack of effectiveness of one
or all the drugs, enhance toxicity, and diminish a treatment’s intended outcome.11
Potential underlying risk factors for DDIs in cancer patients include mucositis and
malnutrition causing impaired absorption, edema resulting from changes in a drug’s
volume of distribution, or excretion changes from renal and/or hepatic dysfunction.12
Other factors include a patient’s age, narrow therapeutic index of the drugs involved,
and physiologic make-up.13 DDIs may lead to various negative outcomes, including
new health complications among patients with cancer,13 and falls resulting in fractures
which may cause delays in cancer treatments and alter the trajectory of the disease,
care planning, or prognosis.14
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A health complication (HC) is defined in this study similarly to an adverse
event, as a possible negative outcome resulting in patient harm or injury due to use of
prescribed medications,15 including medication errors, adverse drug reactions, allergic
reactions, and overdoses.16

To the authors’ knowledge, PP associated with HCs in newly diagnosed cancer
patients have not been thoroughly investigated in a large administrative claims
database. The primary objective of this study was to estimate and describe the
frequency of HCs in newly diagnosed cancer patients, with or without polypharmacy,
in a multivariable framework.
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3.3 Methods

Study design and data source
We conducted a retrospective cohort study to estimate the associated risk
(odds) of having ≥ 1 health complication (HC) with PP among newly diagnosed adult
cancer patients, controlling for various demographic attributes and clinical
characteristics of those patients. The data source used was Optum Clinformatics®
DataMart (Optum, Eden Prairie, MN, USA), years 2010-2015. The database contains
de-identified claims information with the following data tables: eligibility of privatelyinsured members, medical inpatient and outpatient professional services, inpatient
services, outpatient prescription dispensings, and inpatient facility details. Patients
were linked through a common identifier across the various claims tables to ensure all
encounters are captured. The database is comprised of approximately 35 million
unique commercially-insured patients in the US and their captured medical
encounters.

Sample selection
The study population included adult individuals (≥ 18 years old) with an
incident diagnosis of cancer (breast, prostate, colorectal, and lung) who had
continuous enrollment in medical and prescription insurance throughout a 12-month
lookback period through the end of follow-up for the first year following cancer
diagnosis. Female breast, prostate, colorectal, and lung cancer cases were selected for
our study because they are considered the four major cancers by the American Cancer
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Society.14 A patient had to have at least 2 cancer diagnosis claim codes (including in
situ and metastasis), defined by the International Classification of Diseases, 9th
Edition, Clinical Modification (ICD-9-CM) classification system, in the primary or
secondary diagnosis field, which were at least 30 days apart in either the outpatient or
inpatient setting (Appendix E). The patient’s first cancer diagnosis was their index
date. Patients with claims of a personal history of cancer within one year prior to their
first ICD-9-CM code matching were excluded from the algorithm. Individuals were
excluded if their incident diagnosis was not between January 1, 2011 and September
30, 2014. Men with breast cancer were excluded because the focus was on the four
most commonly occurring cancers in the US. If an individual did not have any
pharmacy claims in the year of follow-up they were excluded. People with more than
one type of cancer were excluded, except those with metastatic codes to capture
advanced stage diagnoses. Patients with less than one full year of data following
incident diagnosis were excluded, including those who died. Figure 1 shows the
inclusion and exclusion criteria in greater detail.

The key independent variable (IV) of interest was PP, defined as a patient
filling ≥ 5 distinct medication classes at an outpatient pharmacy in the first quarter (3
months) following incident cancer diagnosis, not accounting for overlap or switching,
with a cumulative sum of days’ supply of at least 7 days, during the 3-month exposure
window after the index date. Since no clear definition of PP exists in the literature,2 we
chose our definition based on published literature which used distinct therapeutic
classes.17,18 These factors, coupled with other research which stated that no single cut-
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point was optimal in defining PP in cancer patients,19 but that ≥ 5 daily medications
was a reasonable threshold for predicting multiple adverse events in elderly cancer
patients, informed our decision to use ≥ 5 therapeutic classes as our threshold for PP.
However, to examine medication use with more accuracy and in a shorter time period
than the aforementioned study, we used a claims database study. Medication classes
were categorized using the American Hospital Formulary Service (AHFS)
Pharmacologic-Therapeutic classification system.20 Vaccinations, due to one-time
administrations, and vitamin (A-E), due to their tendency to be more over-the-counter,
medication classes were excluded from this definition.21

Dependent variable
The primary outcome variable of interest was nonfatal health complications
(HCs), and was dichotomized to either 0 (zero) HCs or ≥ 1 HC. HCs consisted of both
specifically coded adverse drug-related events (ADEs) and other health conditions that
are often associated with adverse effects of medications (e.g. organ toxicity, blood
dyscrasias, falls). HCs were grouped into the following clinically meaningful
categories: cardiovascular (CV), central nervous system and psychiatric (CNS),
gastrointestinal (GI), hematologic (HEMA), metabolic (METB), skeletal (SKEL), and
miscellaneous adverse drug-related events (ADE). The categories were curated from
published literature based on their relevance to patients with cancer, PP, or both.22,23
The outcomes selected were based on current literature and have been either (1) well
documented in cancer patients,15,22,23,24,25,26,27,28,29,30,31 and/or (2) were considered more
likely in people with PP.32,33,34,35,36 The goal of choosing these outcomes was to
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provide a selective list of short-term events which could have been precipitated by the
combination of drugs in a population with a lowered immune system, mostly elderly
(≥ 65), and who may have been increasing their medications due to anticancer
treatment. Clinical events related to common drug interactions in one study included
deep vein thrombosis, upper digestive hemorrhage, various other forms of bleeding,
and neutropenia.15 Other studies mentioned the risk of falling in elderly due to PP,47 or
in those with cancer because of the risk to treatment delays and potential cancerrelated outcomes as a result.30,33 Other examples of specific HCs include fractures and
arrhythmias (See appendix H for full list). HCs were measured in patients with cancer
by using a claims-based algorithm searching for these complications using ICD-9-CM
diagnosis codes. As part of the inclusion criteria, patients had to have continuous
enrollment in both medical and prescription claims for the year following their
incident diagnosis, thus they were alive throughout follow-up. The follow-up period in
which these HCs were measured was during the 3 quarters following the exposure
period (quarter 1) in which the presence of PP was determined.

Covariates
Demographic covariates were assessed during the 12-month baseline period
and included age, sex, and geographic region. Clinical variables assessed at baseline
included type of cancer, insurance plan-type, and Elixhauser comorbidity score.
Radiation and chemotherapy treatments were assessed after exposure. Cancer type was
grouped in the following manner: breast (female only), prostate, lung, and colorectal
using the ICD-9-CM codes listed in Appendix E. We chose to use the Elixhauser
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comorbidity score, excluding the 3 codes related to cancer, to assess physical and
mental diseases and disorders based on the variety of ailments contained within, and
its well-established validity.37 The Elixhauser comorbidity score is the summation of
various comorbid conditions which are dichotomized to represent a condition’s
presence (1) or absence (0) (Appendix F). We categorized the scores based on the
overall distribution into 3 categories 0, 1-2, ≥ 3 conditions. Patients with both
complicated and uncomplicated diabetes, or hypertension, diagnoses claims were
assumed to have the more complicated stage of the disease for these analyses. This
method was used to prevent double counting of the disease if a patient had both
claims. Anticancer infusions and injections were identified using Healthcare Common
Procedure Coding System (HCPCS) coding system in the outpatient setting (J codes
J8500-J9999). The HCPCS coding system classifies similar medical products into
categories for efficient claims processing.38 If the individual received either an
outpatient pharmacy prescription and/or a J code for an antineoplastic agent during the
year following their incident diagnosis, they were defined as receiving active
chemotherapy. Radiation was defined through Current Procedural Terminology (CPT)
and HCPCS G codes (Appendix G).39,40

Statistical analysis
Descriptive statistics were used to describe the proportions of cancer patients
by PP for each covariate. Chi-square tests were used to determine the statistical
significance between PP and categorical covariates, as well as between PP and HCs.
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Also, the percentages of PP in patients with a HC were described according to the type
of cancer. Lastly, to provide information on the number and percent of different
medication drug classes filled by those with or without PP, the 20 most filled
medication drug classes were described.

Logistic regression (LR) modeling was used to examine associations between
individual covariates and HCs. Variables which had statistically significant (p-value
<0.10) association with both PP and HC were used in the multivariable LR modeling
process. The multivariable LR model examined the relationship between PP and HCs,
controlling for the covariates which were significantly related to both PP and HC in
the univariate LR models. Collinearity amongst covariates was assessed by examining
the condition indices and variance decomposition proportions.41 However, no two
independent variables were collinear and thus no variables were removed at this stage.

Covariates were added to the model sequentially based on their negative 2 Log
Likelihood statistic (-2 Log L). Model comparisons were assessed through the
Likelihood Ratio Test (LRT) which produced comparison statistics among models
based on their intercept and covariates using the -2 Log L, where a better fitting model
had a lower -2 Log L value.41 A manual stepwise elimination process was used to
remove variables with p-values higher than 0.05 significance to determine which of
the remaining variables were still significant in the multivariable model. Lastly,
comparison between model performance were assessed by changes in Akaike
Information Criteria (AIC), and goodness-of-fit was tested by changes in c-statistic
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(concordance index) values.42 The measure of effect was the adjusted odds ratio (aOR)
comparing the risk (odds) that a person having PP experienced a HC versus those
without PP, controlling for all other significant covariates.

The objective of a secondary analysis was to examine the relationship among
PP with HCs by type of cancer, controlling for significant covariates (Table 3). To
understand the relationship, four models were created (one for each cancer type) by
first including the following covariates: sex (only for colorectal and lung cancers),
age, region, insurance, comorbidity score, radiation therapy, and chemotherapy
treatment. In these analyses, a manual backward elimination process was used to
remove covariates that were not significant. First, the variable with the largest p-value
(> 0.05) was removed. Next, the model was reanalyzed to determine if any of the
remaining covariates became or remained insignificant. If a variable was insignificant
(p-value >0.05) it was removed. This process was continued until only significant
variables remained in the model. All statistical analyses were conducted using SAS
software, version 9.4 (SAS Institute Inc., Cary, NC, USA).
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3.4 Results

The analytic cohort consisted of 35,336 adult cancer patients (Figure 1). Of
these, 14,573 (41.2%) adults were defined as having PP in the first quarter following
incident cancer diagnosis (Table 1). The cohort had the following characteristics: men
(51.2%), ≥ 65 years (61.8%), were not actively on chemotherapy (68.3%) or radiation
therapy (79.8%) and had ≥ 1 comorbid condition (68.8%). Of those with PP, 70.5%
were ≥ 65 years, 52.5% were women, 43.1% had breast cancer, 37.4% were on
chemotherapy, 19.9% received radiation therapy and 42.2% had ≥ 3 comorbid
conditions (Table 1). In total, 8,891 (25.2%) people with cancer had ≥ 1 HC in the
follow-up period (Table 1). Of those, 4,963 (34.1%) had at least 1 HC in the 3 quarters
during follow-up.

The proportion of adult cancer patients with PP and ≥1 HC as compared with
those who did not have PP were significantly higher (p-value < .0001) across all HC
groups (Table 1). The proportion of patients with PP and ≥ 1 cardiovascular (CV)
event was 19.2% compared to patients without PP who had ≥ 1 CV event (8.9%). The
other differences in proportions were as follows: CNS 5.2% vs. 2.4%, GI 2.8% vs.
1.6%, HEMA 9.9% vs. 5.5%, METB 3.8% vs. 1.1%, SKEL 5.6% vs. 3.5%, and ADE
3.8% vs. 2.4%, per year during follow-up. All counts and percentages for this analysis
are presented in Table 1. All differences were statistically significant at the alpha =
0.05 level.
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Prescription medications
A total of 155,735 prescriptions were filled during the exposure window
(Table 2). Of those, 107,619 (69.1%) were filled by those defined as having PP. The
20 most filled medication classes amounted to 63.9% of total fills for those without PP
compared with 54.4% in the PP group. The classes of medications were similar in both
groups, with HMG-CoA reductase inhibitors being filled the most for PP (7.3% of fills
for PP) and no PP (9.8% of fills for No PP). For the 20 most filled medications,
differences existed between those with and without PP for a handful of classes. For
example, loop diuretics (1.7%), sulfonylureas (1.6%), anticonvulsants (1.6%), and
metformin (1.5%) were top 20 filled medications by people with PP, but not those
without PP. Conversely, first generation cephalosporins (2.0%), corticosteroids
(1.4%), aminopenicillins (1.3%), and anti-inflammatory (skin) agents (1.2%) were in
the top 20 for those without PP, but not those with PP.

Health complications
Figure 3 highlights percentage of patients with ≥1 HC by type of cancer, with
or without PP. Regardless of cancer type, patients with ≥1 HC had a higher percentage
of PP. Patients with lung cancer and HCs had the highest percentage of PP (73.1%).
Conversely, men with prostate cancer and ≥1 HC had the lowest percentage of PP
(51.2%).

Presented in Figure 4 are the percentages of HCs by PP for each type of
cancer. Across each type of cancer CV complications occurred the most, with HEMA
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HCs as the second most frequent. Differences between PP and no PP groups were
statically significant at p-value < 0.05 for each cancer type, with the exception of GI in
colorectal and lung, and skeletal in lung.

Primary analysis: association between PP and nonfatal HCs
To determine the association between PP and nonfatal HCs in the analytic
cohort, a multivariable LR model was created controlling for age, region, type of
cancer, comorbidity burden, radiation therapy, and chemotherapy (Figure 4). Excluded
from this analysis were sex (due to the gender-specific nature of breast and prostate
cancers) and insurance type (due to its insignificance during the model building
process described in the Methods section). PP was associated with a 31% increase in
the risk of having ≥ 1 HC (aOR 1.31, 95% CI: 1.27-1.35, p-value <.0001) in the
follow-up period when controlling for the covariates. Breast and prostate cancers were
significantly associated with decreased risk of having ≥ 1 HC compared to colorectal
cancer (aOR 0.83, 0.79-0.87, p-value <.0001 and aOR 0.84, 0.81-0.87, p-value <.0001
respectively). Whereas lung cancer had a significantly increased risk for ≥ 1 HC
compared to colorectal cancer (aOR 1.23, 1.13-1.23, p-value <.0001).

Chemotherapy and radiation treatments were both significantly associated with
a slightly increased risk of having ≥ 1 HC in the final multivariable LR model (aOR
1.07, 1.03-1.10, p-value <.0001 and aOR 1.06, 1.02-1.10, p-value= 0.0012,
respectively). Age ≥ 75 years old was significantly associated with an increased risk of
having the outcome of interest compared to those aged 50-64 years (aOR 1.39, 1.33-
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1.45, p-value <.0001). The Northeast was significantly associated with an increase in
risk of having ≥ 1 HCs compared to those in the Midwest (aOR 1.08, 1.02-1.14, pvalue= 0.0088). Figure 4 presents additional results pertaining to comorbidity level
and use of chemotherapy or radiation.

Secondary analysis: associations between PP and HCs by type of cancer
Four multivariable logistic regression models were created to assess the
association between PP and HCs for each type of cancer (Table 3). As mentioned
previously, sex was excluded as an explanatory variable from the analysis for breast
and prostate cancers, due to those cancers being sex-specific. Across all four models
PP, age, and comorbidity were significant predictors of HCs. The association between
PP and ≥ 1 HC and other main findings by type of cancer are described next.

In the model for women with breast cancer, PP was associated with a 37%
increase in the odds of having ≥ 1 HC in the follow-up period (aOR 1.37, 1.31-1.42, pvalue <.0001) compared to those without PP. Each age group was significantly
different from those aged 50-64 years old, with the oldest having a 26% increase in
risk (aOR 1.26, 1.17-1.35, p-value <.0001). The West was the only region
significantly different from the Midwest and associated with a decreased risk of
having ≥ 1 HC by 18% (aOR 0.82, 0.77-0.88, p-value <.0001). The number of
comorbid conditions and radiation therapy were significant, but chemotherapy was not
(Table 3).
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In the model for prostate cancer, PP was associated with a 27% increase in the
risk of having ≥ 1 HC (aOR 1.27, 1.22-1.32, p-value <.0001). Younger age (18-49
years) was associated with a 35% decreased risk of ≥ 1 HC (aOR 0.65, 0.51-0.83, pvalue = 0.0004); whereas the oldest aged group (≥ 75 years) had a significantly higher
risk (aOR 1.71, 1.55-1.88, p-value <.0001) compared to those aged 50-64 years. Each
region was significantly different from the Midwest, with the Northeast associated
with an increased risk of ≥ 1 HC (aOR 1.12, 1.02-1.23, p-value = 0.0143). Similar to
breast cancer, chemotherapy was not significantly associated with HCs. Unlike breast
cancer, radiation therapy was insignificant. Table 3 includes findings for age, region,
comorbidity level, chemotherapy, and radiation.

PP was associated with 26% increase in the risk of having ≥ 1 HC (aOR 1.26,
1.16-1.36, p-value <.0001) in people with colorectal cancer when controlling for age,
region, comorbidities, and chemotherapy. Unlike breast and prostate cancers,
chemotherapy was significantly associated with an increased risk of having the
outcome of interest for those with colorectal cancer (aOR 1.35, 1.21-1.50, p-value
<.0001). Age followed the same pattern as prostate cancer, where younger age was
associated with a decreased risk of having ≥ 1 HC (aOR 0.61, 0.49-0.75, p-value
<.0001), and older age was associated with an increased risk (aOR 1.73, 1.52-1.97, pvalue <.0001). Table 3 includes findings for age, sex, region, comorbidity level,
chemotherapy, and radiation.
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Lastly, for those with lung cancer, PP was associated with a 25% increased risk
of ≥ 1 HC (aOR 1.25, 1.11-1.40, p-value =0.0002). Unique to those with lung cancer
was the significant increased risk associated with the person’s sex. Men were 22%
more likely to have ≥ 1 HC compared to women (aOR 1.22, 1.10-1.36, p-value =
0.0002). Both chemotherapy (aOR 1.33, 1.15-1.54, p-value <.0001) and radiation
treatment (aOR 1.25, 1.10-1.36, p-value = 0.0188) were associated with increased
odds of having ≥ 1 HC. Unlike the other cancer types, the analyzed regions were not
associated with a significant difference in risk for people with lung cancer compared
to the Midwest. Model fit (c-statistic) values for each are presented in the notes section
at the bottom of Table 3.
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3.5 Discussion

We used a large administrative claims database to describe the association
between PP and the risk of having ≥ 1 HCs among newly diagnosed patients with
breast (female), prostate, lung, and colorectal cancer controlling for significant
covariates (age, sex, radiation therapy, chemotherapy, comorbid conditions, and
geographic region). We also estimated associations between each type of cancer and
HCs controlling for those covariates. In each multivariable LR model, PP was
associated with a greater than 25% increase in the risk of having ≥ 1 HC.

Polypharmacy
In our study, we found that greater than 40% (2 in 5) of adult patients with
newly diagnosed breast, prostate, colorectal, and lung cancers were defined as having
PP in the first quarter following diagnosis. One study, which defined PP as ≥ 5 distinct
medications, reported the prevalence of PP to be 64% in cancer survivors; however,
this was a cross-sectional study with a more liberal definition of polypharmacy, which
summed the medications used over two years.43 Three studies reported the overall
prevalence of PP in newly diagnosed cancer patients to be 80% (patients aged ≥ 65
years in US),3 57% (in patients aged ≥ 70 years in Australia),44 and 35% (patients also
≥ 70 years in Denmark).45 However, all studies varied in their setting and collection
methods. In the study that reported overall PP of 35%, lung cancer had the highest
percentage of patients with PP (40.9%), compared to the other types of cancer: 32.9%
(breast), 29.9% (colorectal), and 32.3% (prostate).45 These rates were slightly lower
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than our results; however, that study was a case-control study where the controls did
not have a cancer diagnosis at the index date. Although we did not have the same
study design or source population, our results showed that PP, by type of cancer, was
also highest in patients with lung cancer (64.0%).

PP was associated with a significantly higher risk of having ≥ 1 HC in all
analyses, including unadjusted and adjusted LR models. By grouping HCs, we found
that cancer patients with PP had higher proportions of HCs for different body systems
compared to those without PP. For example, complications involving the
cardiovascular system were more than double (19.2%) in patients with PP compared to
those without PP (8.9% p-value <.0001). A study by Barber et al found that certain
hormone therapies in breast and prostate cancer patients increased cardiac
arrhythmias.24 In a review of the impact chemotherapy has on cardiac arrhythmias,
Tamargo et al reported inducement of a direct cardiac effect that can also be initiated
or maintained by substrates created by comorbid conditions or the chemotherapy.25
Hematologic HCs were the second most common, with 9.9% of patients with PP
having at least one compared to 5.5% in those without PP. The hematologic HCs
included in this study are well-established outcomes in patients with cancer; especially
venous thromboembolisms and pulmonary embolisms which are known to increase
after surgery and chemotherapy treatment.26

The results of the primary analysis showed that PP was highly significant in its
association with the risk of having HCs by 31% when controlled for age, region, type
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of cancer, comorbidity, chemotherapy, and radiation therapy. This means that patients
with PP, which comprise 40% of those newly diagnosed with the four most common
types of cancer, have a 31% higher risk of health complications overall. Polypharmacy
has been associated with increased use of potentially inappropriate medications, which
can cause adverse health outcomes among older patients. According to a study by
Lund et al, which analyzed the Surveillance, Epidemiology, and End Results (SEER)Medicare database, among 19,318 breast, 7,283 colon, and 7,237 lung cancer patients
age 66 years and older, the number of PIMs changed after initial diagnosis of cancer
during follow-up (6-23 months duration).27 The increase in PIM dispensing was
directly related to chemotherapy initiation in the first six months. They reported that
for women with breast cancer PIMs decreased, while those with colon or lung cancer
saw an increase. In our analysis, a decreased aORs for breast cancer patients, and
increased aORs for lung, compared to the reference group (colorectal cancer) may be
caused by a similar PIM risk. Lund et al did not study prostate cancer, but with the
watchful-waiting or active surveillance approach recommended by the National
Comprehensive Cancer Network (NCCN), a lack of additional medications for
treatment may also decrease the risk of PIMs and thus decrease the odds of HCs.46

The secondary analysis of PP among cancer types revealed cancer-specific
differences for PP and some of the covariates. PP had the largest estimated risk in
breast cancer patients of the four main cancers, with an increased risk of 37%. One
explanation for this may be the influence of the covariates, specifically that
chemotherapy was not significantly associated with HCs. Lund et al found that of

98

19,318 newly diagnosed patients with stage I-III breast cancer, PIMs declined (40% to
34%) after diagnosis and leveled off as chemotherapy use was curtailed beginning 3
months after incident diagnosis until 23-months follow-up.27 For women with early
stage breast cancer, they often receive surgery followed by radiation then hormone
therapy, but not chemotherapy.47 According to Edwards et al, women with any number
of comorbid conditions are less likely to receive chemotherapy compared to those who
have none.48 Therefore, for the women who receive chemotherapy, they may have an
advanced stage of breast cancer, and the risk of complications would not be
significantly different. Our results showed that women between the ages of 65 and 74
years had a lower risk of HCs compared to those 50-64 years and this lack of
chemotherapy may be why. As chemotherapy is not recommended for early stages of
breast cancer in adults over 70,48 or with having a high number of comorbidities, our
findings suggest that these newly diagnosed breast cancer patients were in situ or
invasive, but not metastatic. Whereas, those aged ≥ 75 years had the highest number of
comorbid conditions (38.5%: not shown) compared to the reference group which had
the largest percentage without comorbidity (35.5%: not shown). Also, radiation
therapy was associated with more HCs which is logical since side-effects linked to
radiation therapy may lead to exacerbating underlying conditions. The youngest age
group was associated with a higher risk for HCs, which could be explained by 58%
(not shown) of those aged 18-49 having no comorbidities, indicating they may have
had a more aggressive form of cancer, as 59% of those aged 18-49 received
chemotherapy treatment compared to 56.0% in the reference group. This higher rate of
chemotherapy may have directly led to an increase in HCs.
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Patients with prostate cancer and PP had a 27% increased risk of having ≥ 1
HC when controlling for age, region, and comorbidity score. Like patients with breast
cancer, chemotherapy was not significantly different between those who had ≥ 1 HC
and those who had none during follow-up. One explanation would be that men with
prostate cancer tend to be diagnosed in their late 60s and early 70s, and the median age
in this study was 69 years. Standard of care for patients with low-risk prostate cancer
thus does not usually involve chemotherapy but may include hormone therapy.
Radiation therapy was also not significantly associated with the outcome of interest.
Differences in HCs from those 50-64 years old were also significant for those 18-49,
but in prostate cancer younger age was protective (35% decrease in risk) because
younger people, on average, had fewer comorbidities (43.4% of 18-49 had none
compared to 31.7% in 50-64, 25.1% in 65-74, and 28.7% in ≥75) . Whereas those aged
65-74 were not significantly different than the reference group, but those ≥ 75 were
significantly associated with an increased risk (71%) for HCs.

Patients with colorectal cancer and PP had a 26% increase in risk of having ≥ 1
HC. Unlike breast and prostate cancer, colorectal cancer occurs in both men and
women. However, in the analysis men and women did not significantly differ in risk
for the outcome. As with prostate cancer, younger age (18-49) was associated with a
decreased risk (39%) and older age with increased risk (73%) of HCs. Also differing
from breast and prostate cancer patients, chemotherapy was associated with an
increased risk of HCs (35%). One explanation for the lowered risk in younger people,
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despite an increased risk associated with chemotherapy, could be that younger people
had the lowest number of comorbidities (34.1% had none in 18-49 years old)
compared to the referent age group (25.5%). Conversely, 75% of those ≥ 75 years had
at least 1 comorbid condition.

PP was associated with a 25% increase in risk for the outcome in patients with
lung cancer after controlling for sex, age, comorbidity, chemotherapy, and radiation.
Men had a 22% higher risk for having ≥ 1 HC than women. Again, since men smoke
more and have shorter life spans in general than women, so at the advanced age when
being diagnosed with lung cancer we would expect men to have a greater risk for HCs.
Both chemotherapy and radiation were significant. We would expect this to be the
case since most lung cancers are diagnosed at a late stage.49 Although surgery may be
undertaken in limited scope, treatment often relies on chemotherapy and radiation to
eliminate the disease. Having 3 or more comorbid conditions compared to no
conditions increased the risk by 69%. Comorbid conditions such as COPD and
emphysema are known to occur in people with lung cancer at diagnosis, which would
increase the risk of having HCs.

We also noted differences in the association between HC events and type of
cancer in the final multivariable LR model. In breast and prostate cancer patients,
results showed these cancer types were less likely to have a HC compared to
colorectal or lung cancer, and may be explained, in part, by the status of chemotherapy
treatment. Being on chemotherapy treatment in both breast and prostate cancers was
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not significantly associated with HCs in their respective models (Table 2). In one
study, which measured drug-related problems (DRP) (e.g. inappropriate drug, adverse
drug reaction) in elderly (mean age 71.1 years) cancer patients, 77.6% were taking ≥ 3
chronic medications concurrently with intravenous chemotherapy and reported to have
an average incidence of 3 DRP.31 Interestingly, adverse drug reactions were reported
to be caused by chemotherapeutic agents 85% of the cases; whereas, potential drugdrug interactions were related to chronic use medications 92.6% of the cases.31 Similar
to this analysis, the study on drug-related problems found a statistically significant
increase in the odds of having a DRP when taking ≥ 5 medications.31 However,
intensity and duration of chemotherapy were unmeasured confounders in the analysis.
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3.6 Limitations

Although efforts were made to address temporality by defining PP in the 1st
quarter following incident diagnosis, no assurances can be made that the individual
was actively taking the medication preceding the event, or that any combination of
medications directly caused the event to occur. Also, although comorbid conditions
were controlled for with a summary score, no assessment was made in baseline to
assess if the HCs were incident cases, thus allowing for the HCs to be chronic in
nature. Further research is warranted that would focus more closely on individual
cancers and HCs resulting from concomitant use of medications.

As with any administrative database analysis, the underlying data may lead to
misclassification of some individual’s cancer or comorbid status. Neither severity nor
stage of cancer are included within the database as standalone variables, and hence
were not controlled for in the analyses. As such, determination of stage or grade of
cancer was not possible. Stage or grade of tumor would be a critical confounding
variable, as these would determine the course of action for these patients regarding
surgery, chemotherapy, and radiation treatments.

We were unable to conduct any analyses regarding race, as we did not have
this variable in the database. Incidence rates for the four most common cancers studied
in this manuscript vary by race. For instance, African Americans have higher
incidence rates for prostate, colorectal, and lung cancers compared to White, Hispanic,
and other racial/ethnic groups.50
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Intensity of infusion chemotherapy nor strength or dosing of prescription
anticancer agents were analyzed for this analysis. The definition used to classify a
newly diagnosed cancer patient as PP was based on the number of distinct medication
classes and a minimum days’ supply during the first quarter following diagnosis. This
definition inherently may lead to under- or overestimation of the number of patients
with PP because most adherence rates for chronic medications would require reaching
80% adherence. Some definitions of PP have counted individual medications,
including counting infusions over their day of activity, which would mean counting
them more than once per month to account for administration cycles. Also, we did not
account for infusions or injections which may have not been related to anticancer
treatment. The focus of defining PP was for outpatient pharmacy filled medications
and therefore inpatient drug usage, over-the-counter, and complementary and
alternative drugs were not included as potential contributors to PP in this analysis.
Although medications were described in this analysis, no formal statistical tests were
conducted to assess associations between their concomitant use and HCs. We
examined common HCs associated with PP and cancer patients. The study was
designed to use medication class because the mechanism of action within drug class
would be the same despite different ingredients.
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3.7 Conclusions

Newly diagnosed patients with breast, prostate, colorectal, or lung cancer who
had PP were all at a higher risk of having ≥ 1 health complication compared to those
without PP. When analyzing by type of cancer and controlling for age, sex,
comorbidity, chemotherapy and radiation therapy, PP was associated with an
increased risk of HCs by over 25% per cancer type. Active chemotherapy treatment
was associated with increased risk of HCs in colorectal and lung cancer patients, but
not in breast or prostate cancer patients.
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Figure 1. Selection of Patients for Analyses of Health Complications in Adults (≥ 18 years) Newly
Diagnosed with Cancer, with or without Polypharmacy, in Optum Clinformatics Data Mart 20112014.

818,119
682,653 (83.5%)

Patients with any diagnosis claim in any
claim position for female breast,
prostate, colorectal, or lung cancer
between 1/1/2010 - 9/30/2015

•

•
•

•
135,466 (16.5%)

Excluded patients without 2
primary or secondary diagnosis
claims (128,228; 15.7%), or if
< 30 days between index claim and
second claim (153,838; 18.8%),
index date not in study window
(1/1/2011 – 9/30/2014) (244,960;
30.0%), or
without continuous enrollment 365
days before/after index date
(155,627; 19.0%)

Cancer patients meeting algorithm
criteria for cancer case and enrollment
eligibility
1,013 (0.12%)
•
•
•

134,453 (16.2%)
Cancer patients meeting demographic
criteria

99,117 (12.1%)
•
•
•

35,336 (4.3%)
Newly diagnosed adult cancer patients
in study sample

•

•
20,763 (58.8%)

14,573 (41.2%)

No Polypharmacy

Polypharmacy

Excluded patients <19 or >90 years
old (58; <0.1%),
unknown gender (40; <0.1%), and
unknown State information (915;
0.11%)
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Excluded men with breast cancer
(110; <0.1%),
women with prostate cancer (21;
<0.1%), and
people with metastatic or cancers
that are not 1 of 4 investigated
cancers, excluding benign (92,595;
11.3%),
people without an outpatient
prescription filled within 365 days
following index (5,977; 0.7%), and
people who died within 365 days of
index (414; <0.1%)

Figure 2. Study Window Timeline (not to scale)

1/1/2010

Index Date: First claim for cancer (no
earlier than 1/1/2011, no later than
9/30/2014)

Lookback Period:
365 days pre-index
Baseline Assessment:
No other cancer(s)
diagnosed, continuous
enrollment, and
comorbidity assessment

Polypharmacy:
≥ 5 distinct
classes of
prescription
drugs filled for ≥
7 days in quarter
1 following the
index date

9/30/2015

Follow-up Period: Health
complications assessed during quarters
2 through 4. Chemotherapy and
radiation therapy assessed in quarters
2 through 4.
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Table 1. Demographic and Clinical Characteristics of Adults (≥ 18 years) with Newly Diagnosed
Cancer by Polypharmacy Status During 2011-2015, (N= 35,336).
Demographic and Clinical
No Polypharmacy
Polypharmacy
Characteristics of Cancer
p-value
(N= 20,763 | 58.8 %)
(N= 14,573 | 41.2 %)
Survivors
Age group (years)
18-49
2,014 (9.7)
688 (4.7)
50-64
7,189 (34.6)
3,618 (24.8)
<.0001
65-74
6,525 (31.4)
5,142 (35.3)
≥ 75
5,035 (24.3)
5,125 (35.2)
Sex
Men
11,164 (53.8)
6,926 (47.5)
<.0001
Women
9,599 (46.2)
7,647 (52.5)
Region
Northeast
2,099 (10.1)
1,384 (9.5)
South
7,531 (36.3)
5,514 (37.8)
<.0001
Midwest
4,287 (20.6)
2,731 (18.7)
West
6,846 (33.0)
4,944 (34.0)
Insurance Coverage
Commercial
10,439 (50.3)
9,775 (67.1)
Medicare Advantage
10,324 (49.7)
4,798 (32.9)
<.0001
Type of Cancera
Breast (female)
8,422 (40.6)
6,278 (43.1)
Prostate
9,898 (47.7)
5,808 (39.9)
Colorectal
1,854 (8.9)
1,438 (9.9)
Lung
589 (2.8)
1,049 (7.2)
<.0001
Chemotherapyb
Yes
5,764 (27.8)
5,453 (37.4)
<.0001
Radiation Therapy
Yes
4,235 (20.4)
2,905 (19.9)
0.2862
Elixhauser Comorbidity Score (baseline)c
0
8,318 (40.1)
2,703 (18.6)
1-2
9,336 (44.9)
5,721 (39.3)
≥3
3,109 (15.0)
6,149 (42.2)
<.0001
Health Complication (HC)d
Cardiovascular
1,857 (8.9)
2,794 (19.2)
<.0001
CNS and Psychiatrice
495 (2.4)
759 (5.2)
<.0001
Gastrointestinal
333 (1.6)
410 (2.8)
<.0001
Hematologic
1,133 (5.5)
1,449 (9.9)
<.0001
Metabolic
236 (1.1)
559 (3.8)
<.0001
Skeletal
725 (3.5)
812 (5.6)
<.0001
Adverse drug-related event
297 (1.4)
430 (3.0)
<.0001
Patients with any HC
3,928 (18.9)
4,963 (34.1)
<.0001
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Notes: aCodes used to define each type of cancer are in Appendix E.
b
Chemotherapy was dichotomized into two groups based on absence or presence of at least 1
outpatient prescription claim using American Hospital Formulary System (AHFS) of classification
coding or a Healthcare Procedure Coding System Level II (HCPCS) in the range of J8500-J9999 in
the follow-up year post-index claim.
c
Elixhauser Comorbidity Score is the summation of a dichotomized variable for absence or
presence of various health conditions found in Appendix F. In this analysis, 4 of the original 31
disease (states) coding groupings were excluded as 3 related to cancer conditions and 1 related to
an outcome of interest (arrhythmias). Baseline refers to the time from the index date (first cancer
diagnosis) up to 365 days prior to the index date.
d
Code sets for health complications (HCs) are in Appendix G. HCs were assed in the 2nd, 3rd, and
4th quarter following a patient’s incident cancer diagnosis.
e
CNS= central nervous system.
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Table 2. The 20 Most Filled Prescription Medication Classes During the Exposure Window for
Cancer Patients, by Polypharmacy, N,% (N=35,336).
No Polypharmacy
Medication Class

N

%

Polypharmacy
Medication Class

N

%

HMG-CoA reductase inhibitors

4,492

9.8

HMG-CoA reductase inhibitors

7,816

7.3

Angiotensin-converting enzyme
inhibitors
Beta-adrenergic blocking agents

3,047

6.7
5.3

5.1

Beta-adrenergic blocking agents
Angiotensin-converting enzyme
inhibitors

5,686

2,312

5,109

4.8

Antineoplastic agents

2,299

5.0

Dihydropyridines

3,617

3.4

Dihydropyridines

1,748

3.8

Proton-pump inhibitors

3,614

3.4

Opiate agonists

1,613

3.5

3,508

3.3

Angiotensin ii receptor
antagonists
Thyroid agents

1,483

3.3

Opiate agonists
Angiotensin ii receptor
antagonists

2,754

2.6

1,431

3.1

Antineoplastic agents

2,722

2.5

Proton-pump inhibitors

1,346

3.0

Thyroid agents

2,605

2.4

Selective alpha-1-adrenergic
block.agent
Quinolones

1,339

2.9
2.4

2.6

Metformin
Selective-serotonin reuptake
inhibitors

2,589

1,199

2,468

2.3

Selective-serotonin reuptake
inhibitors
Other nonsteroidal anti-inflam.
agents
First generation cephalosporins

954

2.1
Quinolones

1,993

1.9

937

2.1
1.7

2.0

1,847

1.7

Benzodiazepines
(anxiolytic,sedativ/hyp)
Thiazide diuretics

847

1.9

1,844

1.7

808

1.8

Loop diuretics
Benzodiazepines
(anxiolytic,sedativ/hyp)
Selective alpha-1-adrenergic
block.agent
Other nonsteroidal anti-inflam.
Agents

1,869

899

1,773

1.7

Metformin

645

1.4

Sulfonylureas

1,710

1.6

Corticosteroids (eent)

616

1.4

Anticonvulsants, miscellaneous

1,683

1.6

Aminopenicillins

572

1.3

Thiazide diuretics
1,675
1.6
Anti-inflammatory agents (skin,
560
1.2
mucous)
Other diabetes*
1,633
1.5
Notes: Total number of unique prescription classes filled for those without PP and those with PP
were 48,116 and 107,619, respectively.
*= drug class name was diabetes mellitus, but to not confuse it with biguanides (metformin) they are
listed as Other diabetes.
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Figure 3. Percentage of Patients with ≥ 1 Health Complication by Polypharmacy and Body
System during 2nd, 3rd, and 4th Quarters of the Year Following Incident Cancer Diagnosis for
2011-2015 (N=8,891).
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Breast (N=3,557)
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No PP

Colorectal (N=1,035)

Prostate (N=3,683) Colorectal (N=1,035)

PP

Lung (N=616)

Lung (N=616)

HC Group No PP (%) PP (%) No PP (%) PP (%) No PP (%) PP (%) No PP (%) PP (%)
ADE

2.2

4.1

0.7

1.4

1.6

2.9

2.6

4.4

CNS

2.0

5.2

2.5

4.8

3.2

5.6

2.7

7.1

CV

6.9

15.0

10.2

21.2

10.1

24.1

13.6

23.3

GI*

1.2

2.2

1.4

2.8

4.1

5.5

2.6

3.0

HEMA

6.6

11.6

3.9

6.3

7.2

12.6

9.5

16.4

METB

0.5

2.7

1.3

4.0

2.4

6.7

2.9

6.0

SKEL*

3.5

5.7

3.3

5.2

4.0

6.1

4.8

6.0

18.0

32.5

18.2

32.5

24.1

40.9

28.2

42.9

ANY

Notes: HC= health complication; ADE= adverse drug event; CNS= central nervous system and
psychiatric; CV= cardiovascular; GI= gastrointestinal; HEMA= hematologic; METB= metabolic;
SKEL= skeletal. PP= polypharmacy. *= GI HCs for lung and colorectal differences between PP and no
PP were not statistically significant (p-value 0.0556 and 0.7556, respectively), nor for SKEL (p-value
0.3132). All remaining differences between PP and no PP for HC group by cancer type were significant
(p-value < 0.05).
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Figure 4. Adjusted Odds Ratios (aORs) with 95% Confidence Intervals of Significantly
Associated Investigated Variables for ≥ 1 Health Complication, Results of a Multivariable
Logistic Regression Model for Newly Diagnosed Adult (≥ 18 years) Cancer Patients in the US
2011-2015 (N=35,336).
0

0.2

0.4

0.6

Polypharmacy (Yes)
Age group, 18-49*
Age group, 65-74
Age group, ≥75
Northeast
South*
West
Breast
Prostate
Lung
Elixhauser Score, 1-2
Elixhauser Score, ≥3
Chemotherapy (Yes)
Radiation (Yes)

0.8

1

1.2

1.4

1.6

1.8

1.31
1.00
0.88
1.39
1.08
0.98
0.86
0.83
0.84
1.23
0.92
1.54
1.07
1.06

Notes: *= not statistically different from reference group.
Reference categories for the investigated variables above were as follows: No polypharmacy, Age
group 50-64, Midwest region, prostate cancer, Elixhauser score of 0 (zero), not on radiation therapy
(No), and not on chemotherapy (No).
C-statistic for model was 0.66.
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Table 3. Multivariable Logistic Regression Results of Adult (≥ 18 years) Patients with Cancer for
Odds of having ≥ 1 Health Complication, by Type of Cancer, Adjusted Odds Ratios (aORs) with
95% Confidence Intervals (95% CI).
Investigated
Breast
Prostate
Colorectal
Lung
Variable
aORs (95% CI)
aORs (95% CI)
aORs (95% CI)
aORs (95% CI)
Polypharmacy (ref= No polypharmacy)
Yes

1.37 (1.31 - 1.42)

1.27 (1.22 - 1.32)

1.26 (1.16 - 1.36)

1.25 (1.11 - 1.40)

N/A

N/A

NS

1.22 (1.10 - 1.36)

Age group (years), (ref= 50-64)
18-49
1.14 (1.04 - 1.25)
65-74
0.81 (0.76 - 0.87)
≥ 75
1.26 (1.17 - 1.35)

0.65 (0.51 - 0.83)
1.05 (0.96 - 1.16)
1.71 (1.55 - 1.88)

0.61 (0.49 - 0.75)
1.03 (0.89 - 1.18)
1.73 (1.52 - 1.97)

1.66 (0.94 - 2.94)
0.77 (0.61 - 0.98)
1.04 (0.82 - 1.31)

Region (ref= Midwest)
Northeast
1.09 (0.99 - 1.21)
South
1.05 (0.98 - 1.12)
West
0.82 (0.77 - 0.88)

1.12 (1.02 - 1.23)
0.91 (0.86 - 0.97)
0.90 (0.84 - 0.97)

1.00 (0.83 - 1.20)
1.07 (0.94 - 1.21)
0.81 (0.71 - 0.93)

NS
NS
NS

Elixhauser Comorbidity Score (ref= 0)
1-2
0.94 (0.89 - 0.99) 0.91 (0.86 - 0.96)
≥3
1.40 (1.32 - 1.49) 1.70 (1.60 - 1.80)

0.82 (0.74 - 0.92)
1.54 (1.37 - 1.73)

1.11 (0.95 - 1.31)
1.69 (1.45 - 1.96)

Sex (ref= Women)
Men

Chemotherapy (ref= not on treatment)
On treatment
NS
NS
1.35 (1.21 - 1.50) 1.33 (1.15 - 1.54)
Radiation (ref= not on treatment)
On treatment 1.10 (1.05 – 1.15)
NS
NS
1.25 (1.10 - 1.36)
Notes: Models were created for each type of cancer with health complications (HCs) as the
dependent variable. HCs were dichotomized as absent (0) or present ≥ 1 (1).
aORs in bold font indicate statistical significance where the 95% confidence interval did not cross
1.0 at alpha < 0.05.
NS = not significant during backward elimination modeling. Since each type of cancer was modeled
separately, aORs for variables without statistical significance are not shown.
N/A = not applicable to breast and prostate cancer models due to sex-specific inclusions.
Model c-statistics by type of cancer were as follows: breast 0.65; prostate 0.67; colorectal 0.68; lung
0.67.
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APPENDIX A
CANCER DIAGNOSES OF INTEREST FOR STUDY POPULATION
Clinical Classification Codes [CCCODEX] of disease medical codes
Diagnosis (type of cancer)

CCCODEX

Cancer of Head and Neck

11

Cancer of esophagus

12

Cancer of stomach

13

Cancer of Colon

14

Cancer of rectum and anus

15

Cancer of liver and intrahepatic bile duct

16

Cancer of pancreas

17

Cancer of Other GI Organs, Peritoneum

18

Cancer of Bronchus, Lung

19

Cancer; other respiratory and intrathoracic

20

Cancer of bone and connective tissue

21

Melanomas of Skin

22

Other Non-Epithelial Cancer of Skin*

23

Cancer of Breast

24

Cancer of Uterus

25

Cancer of other Female Genital Organ

28

Cancer of Prostate

29

Cancer of Testis

30

Cancer of Other Male Genital Organs

31

Cancer of Bladder

32

Cancer of kidney and renal pelvis

33

Cancer of other urinary organs

34

Cancer of brain and nervous system

35

Cancer of thyroid

36

Hodgkin`s disease

37

Non-Hodgkin's Lymphoma

38

Leukemias

39

Multiple myeloma

40

Cancer, Other and Unspecified Primary

41

Secondary malignancies*

42

Malignant Neoplasm Without Specification

43

Neoplasms of Unspecified Nature or Unknown

44

Benign neoplasm of uterus*

46

Other and Unspecified Benign Neoplasm*

47

* = Excluded from analysis; Codes are available at:
https://meps.ahrq.gov/data_stats/download_data/pufs/h170/h170app3.html#Top
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APPENDIX B
PRIORITY CONDITIONS AND OTHER CONDITIONS INVESTIGATED
Clinical classification codes [CCCODEX] and International Classification of Disease 9 th
Edition [ICD-9] medical codes
Condition
Arthritis (infective & osteomyelitis 201, rheumatoid
arthritis 202, osteoarthritis 203, other non-traumatic joint
disorders 204)

Physical

a

Chronic Obstructive Pulmonary Disease (COPD)
(chronic bronchitis 491, emphysema 492, Bronchiectasis
(494), chronic airway obstruction 496), asthma 128,493
Diabetes (without complications 049, with complications
050)
Heart conditions (acute myocardial infarction 100,
coronary atherosclerosis 101, nonspecific chest pain 102,
pulmonary heart disease 103, other heart disease 104,
conduction disorders 105, cardiac dysrhythmias 106, cardiac
arrest 107, congestive heart failure 108), stroke (hemiplegia
342, cerebrovascular disease 430-438), hypertension
(essential 098, with complications and secondary 099)

Source

Code

CCCODEX

201-204

CCCODEX

ICD9CODX

127, 128
491,492,
493,
494,496

CCCODEX

049, 050

CCCODEX

096-099

ICD9CODX

100-108,
342, 430438

Mood Disorder (depression and bipolar)
ICD9CODX
657
Anxiety
CCCODEX
651
Notes: aPhysical chronic conditions were identified using the information provided by MEPS which
can be found here: https://meps.ahrq.gov/mepsweb/data_stats/MEPS_topics.jsp. bMental conditions
are also from MEPS and can be found here: https://www.hcupus.ahrq.gov/toolssoftware/ccs/AppendixCMultiDX.txt
Mentalb
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APPENDIX C
SETTINGS OF CARE CODES
Medical Expenditures Settings of Care classification codes
Setting of Care
Office-based
Hospital Outpatient

Expenditure Variable
OBVEXP[YY]
OPTEXP[YY]

Emergency Room
ERTEXP[YY]
Inpatient Hospital Stays
IPTEXP[YY]
Prescription Medicines
RXEXP[YY]
Dental
DVTEXP[YY]
Home Health Care
HHHCXP[YY]
Other Medical Expenses
VISEXP[14], OTHEXP[YY]
Note: [YY] represents the placeholder for the 2-digit year associated with the year of the Household
Component file. Example OBVEXP14 would be the office-based variable for the year 2014.
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APPENDIX D
PRIORITY CONDITIONS AND OTHER CONDITIONS INVESTIGATED
Clinical classification codes [CCCODEX] and International Classification of
Disease 9th Edition [ICD-9] medical codes
Medical Condition
Congestive heart failure
Valvular disease
Pulmonary circulation disorder
Peripheral vascular disorders
Hypertension, uncomplicated
Hypertension, complicated
Paralysis
Other neurological disorders

ICD9CODX
CCCODEX
398, 402, 404, 428
108
093, 394, 395, 396, 397, 424, 746
096
415, 416, 417
103
440, 441, 442, 443, 444, 447, 449, 557
114
401, 642
098, 184
401, 402, 403, 404, 405, 437, 642
099, 183, 184
342, 343, 344, 438, 780
082
330, 331, 332, 333, 334, 335, 338, 340, 341,
079, 080, 081
345, 347, 649, 768, 780, 784
Chronic pulmonary disease
490, 491, 492, 493, 494, 495, 496, 500, 501,
127, 128
502, 503, 504, 505, 506
Diabetes, uncomplicated
249, 250, 648
049
Diabetes, complicated
249, 250, 648
050
Hypothyroidism
243, 244
048
Renal failure
403, 404, 585, 586
157
Liver disease
070, 456
150, 151
Peptic ulcer disease, excluding bleeding
531, 532, 533, 534
139
HIV/AIDS
042, 043, 044
005
Rheumatoid arthritis
701, 710, 714, 720, 725
202
Coagulation disorders
286, 287, 289, 649
062
Obesity
278, 649, 793
N/A
Weight loss
260, 261, 262, 263, 783
052
Fluid and electrolyte disorders
276
055
Anemia, blood loss*
280, 648
059
Anemia, deficiency*
280, 281, 285
059
Alcohol abuse
291, 303, 305
660
Drug (substance) abuse
292, 304, 305. 648
661
Psychoses
295, 296, 297, 298, 299
659
Depression
300, 301, 309, 311
657
Note: *= must have both ICD9CODX and CCCODEX codes. Due to inclusion/exclusion criteria for the cancer
survivor population in the study, the Elixhauser coding for lymphoma, metastatic cancer, and solid tumors
without metastasis are excluded as comorbid conditions. MEPS uses 3-digit ICD9CODX and CCCODEX codes.
The search algorithm only counted a medical condition as present or absent, and no double-counting occurred if
a patient had both the ICD9CODX and CCCODEX codes. If a survivor had both diabetes complicated and
uncomplicated, preference was given to complicated. If a survivor had hypertension complicated and
uncomplicated, preference was given to complicated.
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APPENDIX E
CANCER DIAGNOSES OF INTEREST FOR STUDY POPULATION
International Classification of Diseases, 9th Revision, Clinical Modification Codes
Cancer Type
ICD-9-CM Abbreviated Codesa
Breast
174.x, 198.81, 233.0
Colon
153.x, 197.5, 209.13, 209.14, 209.15, 209.16, 230.3
Rectum
154.x, 209.17, 230.42
Prostate
185, 233.4
Lung
162.2-162.9, 197.0, 231.2
Note: Codes include carcinoma in situ and metastatic cancer.
a
HCUP CCS. Healthcare Cost and Utilization Project (HCUP). March 2017. Agency for
Healthcare Research and Quality, Rockville, MD. www.hcupus.ahrq.gov/toolssoftware/ccs/ccs.jsp.
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APPENDIX F
AGENCY FOR HEALTHCARE RESEARCH AND QUALITY (AHRQ)
International Classification of Disease 9th Edition [ICD-9] medical codes for
Elixhauser Comorbidity Score
ICD-9-CM Code29
398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11,
404.13, 404.91, 404.93, 428.x
Valvular disease
093.2, 394.x - 397.1, 397.9, 424.x, 746.3 - 746.6, V42.2,
V43.3
Pulmonary circulation disorder
416.x, 417.9
Peripheral vascular disorders
440.x, 441.x, 442.x, 443.1 - 443.9, 447.1, 557.1, 557.9, V43.4
Hypertension, uncomplicated
401.1, 401.9, 642.0
Hypertension, complicated
401.0, 402.x - 405.x, 546.1, 642.1, 642.2, 642.7, 642.9
Paralysis
342.x - 344.x, 438.2x - 438.5x
Other neurological disorders
330.x - 331.x. 332.0, 333.4, 333.5, 334.x, 335.x, 340, 341.1341.9, 345.x, 347.x, 780.3, 784.3
Chronic pulmonary disease
490x-492.x, 493.x, 494x - 505.x, 506.4
Diabetes, uncomplicated
250.0 - 250.3, 648.0
Diabetes, complicated
250.4 - 250.9, 775.1
Hypothyroidism
243 - 244.2, 244.8, 244.9
Renal failure
403.01, 403.11, 403.91, 404.02, 404.03, 404.12, 404.13,
404.92, 404.93, 585.x, 586.x, V42.0, V45.1, V56.x
Liver disease
070.22, 070.23, 070.32, 070.33, 070.44, 070.54, 456.0, 456.1,
456.20, 571.0, 571.2-571.9, 572.3, 572.8, V42.7
Peptic ulcer disease, excluding bleeding 531.41, 531.51, 531.61, 531.7, 531.91, 532.41, 532.51, 532.61,
532.7, 532.91, 533.41, 533.51, 533.61, 533.7, 533.91, 534.41,
534.51, 534.61, 534.7, 534.91
HIV/AIDS
042.x-044.x
Rheumatoid arthritis
701.0, 710.x, 714.x, 720.x, 725.x
Coagulation disorders
286.x, 287.1, 287.3-287.5
Obesity
278.0
Weight loss
260.x-263.x, 783.2
Fluid and electrolyte disorders
276.x
Anemia, blood loss*
280.0, 648.2
Anemia, deficiency*
280.1-281.9, 285.2, 285.9
Alcohol abuse
291.0-291.3, 291.5, 291.8, 291.9, 303.x, 305.0
Drug (substance) abuse
292.0, 292.82-292.89, 292.9, 304.x, 305.2-305.9, 648.3
Psychoses
295.x-298.x, 299.1
Depression
300.4, 301.12, 309.0, 309.1, 311
Note: Due to inclusion/exclusion criteria for the cancer patient population in the study, the Elixhauser
coding for lymphoma, metastatic cancer, and solid tumors without metastasis are excluded as comorbid
conditions. If a patient had both diabetes complicated and uncomplicated, preference was given to
complicated. If a patient had hypertension complicated and uncomplicated, preference was given to
complicated.
Medical Condition
Congestive heart failure
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APPENDIX G
RADIATION THERAPY CODES
Current Procedural Terminology (CPT) and Healthcare Common Procedure
Coding System (HCPCS)

Description of Procedure
Codes / Code Range
Therapeutic radiology: planning
77261-77263
Radiation therapy simulation
77280-77299
Radiation physics services
77300-77370
Sterotactic radiosurgery
77371-77373
Radiation treatment
77401-77417
IMRT deliverya
77401-77417
Steroscopic imaging guidance
77421
Neutron therapy
77422-77423
Radiation therapy management
77427-77499
Proton therapy
77520-77525
Hyperthermia treatment
77600-77620
Brachytherapy
77750-77799
Ultrasound localization of radiation therapy
G6001
Stereoscopic x-ray guidance
G6002
Radiation Treatment delivery
G6003-G6017
Notes: aIMRT = intensity modulated radiation therapy.
bSources are listed as reference numbers 22 and 23 from manuscript 3.
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Sourceb
CPT
CPT
CPT
CPT
CPT
CPT
CPT
CPT
CPT
CPT
CPT
CPT
HCPCS
HCPCS
HCPCS

APPENDIX H
ADVERSE EVENT CODES
Common Adverse Events and Drug-Related Events in Cancer Patients
Category
Cardiovascular

Central
nervous system
and psychiatric

Adverse event
Conduction disorders;
Cardiac arrhythmias;
Tachycardia
Secondary hypertension and
Hypertension complications;
Hypotension
Seizures/convulsions (not epilepsy);
Myoclonus
Syncope/collapse/faint

ICD-9-CM
426.x,
427.x;
785.0
405.x,
458.x
780.3x;
333.2
780.2

Delirium (acute, subacute),
Drug psychoses
Neuropathy due to drugs

293.0, 293.1;
292.x
357.6

Gastrointestinal

Acute gastrointestinal bleeding

d

Hematologic

Pulmonary embolism or Venous
thromboembolism;
Anemia;
Leukopenia;
Neutropenia;
Thrombocytopenia;
Acute renal failure
Fracture
Dislocationf
Intracranial injuryf
Crushing injuryf
Other head injuries (not included in
fracture above)

Metabolic
Skeletal

Other

Other spinal injuries (not included in
fracture above)
Falls
Unspecified adverse effect of
unspecified drug, medicinal and
biological substance
Poisonings by drugs, medicaments,
and biological substances; and late
effects
Toxic effects of substances
Adverse effects in therapeutic use of
drugs, medicaments, and biologics
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531.0x, 531.1x, 531.3x, 532.0x,
532.1x, 532.2x, 533.0x, 533.1x,
533.2x, 534.0x, 534.1x, 534.2x,
535.01, 535.11, 535.21, 535.41,
535.51, 535.61, 535.71, 578.x
415.1x, 451.x, 452.x, 453.x;
280.x, 281.x, 285.2, 285.9, 648.2;
288.50, 288.51, 288.59;
288.00, 288.03, 288.09;
287.3, 287.5, 289.84
584.x
a
800.xx-829.xx, aE880-E887
f
830.xx-839.xx
f
850.xx-854.xx
f
925.xx-929.xx
g
870.xx–873.xx, 900.xx, 910.xx,
918.xx, 920.xx-921.xx, 950.xx951.xx
g
846.xx-847.xx, 952.xx –954.xx
c

V15.88

b

995.0, 995.20, 995.4

g

960-977; 909.0, 909.5

g

980.xx-989.xx
E930.xx -E949.xx

g

Notes: ICD-9-CM: International Classification of Diseases, Ninth Revision, Clinical
Modification.
a: Ray WA, Griffin MR, Fought RL, Adams ML. Identification of fractures from
computerized Medicare files. J Clin Epidemiol. 1992;45(7):703–14. https://doiorg.uri.idm.oclc.org/10.1016/0895-4356(92)90047-Q.
b: Certain health complications not classified elsewhere. ICD9DATA.com
http://www.icd9data.com/2015/Volume1/800-999/990-995/995/default.htm
c: Kim DH, Schneeweiss S. Measuring frailty using claims data for pharmacoepidemiologic
studies of mortality in older adults: evidence and recommendations. Pharmacoepidemiology
and drug safety. 2014;23(9):891-901. doi:10.1002/pds.3674.
d: Riechelmann RP, Del Giglio A. Drug interactions in oncology: how common are they?
Annals of Oncology 20: 1907–1912, 2009. doi:10.1093/annonc/mdp369.
e: Tamariz et al. A systematic review of validated methods for identifying ventricular
arrhythmias using administrative and claims data. Pharmacoepidemiology and drug safety
2012; 21(S1): 148–153. Published online in Wiley Online Library (wileyonlinelibrary.com)
doi: 10.1002/pds.2340
f: Waters TM, Chandler AM, Mion LC, Daniels MJ, Kessler LA, et al. Use of International
Classification of Disease, Ninth Revision, Clinical Modification, codes to identify inpatient
fall-related injuries. J Am Geriatr Soc. 2013 Dec;61(12):2186-91. doi: 10.1111/jgs.12539.
Epub 2013 Nov 1.
g: Rassekh SR, Lorenzi M, Lee L, Devji S. Reclassification of ICD-9 Codes into meaningful
categories for oncology survivorship research. J Cancer Epidemiol. 2010;2010:569517. doi:
10.1155/2010/569517. Epub 2010 Dec 29.
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